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INTRODUCTION 
Acidifying agents are used orally as dosage forms or as 
feed additives in cats to aid in the prevention of formation 
in the urine of magnesium ammonium phosphate hexahydrate 
crystals. These crystals are commonly called struvite. 
Struvite is the most frequently involved mineral in feline 
uroliths that occur in feline urologic syndrome {FUS}. The 
crystals are more soluble in acid urine and will dissolve at 
low urinary pH. 
An amino acid, dl-methionine, has been used for many 
years as an aid in treatment of urolithiasis and as a 
prevention of further occurrence of struvite crystal 
formation by the acidification of the urine. 
While the hydroxy analogue of methionine {MHA) has been 
used as a d i etary replacement for the amino acid in humans 
and animals, it has not been used specifically as a urinary 
acidifier in cats. If calcium methionine hydroxy analogue 
{CaMHA) can safely be used as a urinary acidifier it may have 
an advantage when compared to methionine since production of 
ammonia cannot occur from MHA, and therefore, MHA will not 
contribute to the body burden of ammonia. 
The purpose of this study was to characterize and 
compare the acute toxici ties in cats of dl-methionine and 
calcium methionine hydroxy analogue at three different doses 
2 
given for a seven day treatment period. An untreated control 
group of animals was included in the study. Confirmation of 
the effectiveness of the two drugs as urinary acidif iers in 
cats and an estimate of the lowest effective dose were also 
objectives . 
Alteration of the composition of feline urine by diet in 
order to prevent FUS should be done without inducing harmful 
side effects. Therefore, the results of this efficacy and 
acute toxicity study may be used as a basis for a long term 
study of CaMHA as a feed additive in the diets of cats as an 
alternative to dl-methionine . 
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LITERATURE REVIEW 
Definition, causes, and Therapy of FUS 
The feline urologic syndrome (FUS) has long been 
recognized as a disorder of the lower urinary tract of cats. 
The term feline urologic syndrome is now considered 
synonymous with feline lower urinary tract disease and 
represents a variety of disorders. 1 Clinical signs of FUS 
generally include hematuria, dysuria, and crystalluria. The 
causes may be single, multiple and interacting, or unrelated. 
It is, therefore, a multifactorial disease syndrome, which is 
often recurrent in its nature. The roles of diet, 
etiological agents and other predisposing factors have not 
been completely elucidated. 21314 Bacterial infection is 
rarely an initiating cause of FUS, 516 but may be a 
complication as a result of instrumentation used in treating 
the clinical condition7 and may be involved in the 
recurrence of FUS. 8 A herpes virus has been suggested as a 
cause of FUS. 9 Others have found after intensive studies 
that if viruses contribute to FUS their role is minor . 6110 
A nutritionally balanced dry diet was found to be unlikely as 
a cause of FUS. 11 A review of epidemiological studies that 
have been conducted on FUS also concluded that no single 
factor is entirely responsible for all cases. 12 One survey 
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of households containing cats determined the incidence of FUS 
in the cat population of the United States to be 0.85%. 13 
Feline urolithiasis, while commonly used as a synonym 
for FUS, is one of the subsets of causes of lower urinary 
tract disease . 1' 2' 3' 4 Epidemiological studies of feline 
uroliths have shown that 88 percent of naturally occurring 
uroliths were composed of at least 70 percent struvite and 
that 68 percent were composed of 100 percent struvite . It 
was also found that 94 percent of urethral plugs were 
composed primarily of struvite and 4 percent were composed of 
matrix only . The implication is that only struvite is of 
great clinical importance because of the infrequency of non-
struvi te minerals in urethral plugs. 14 A five year update 
of this study published in 1989 revealed a continuation of 
the finding that struvite is the principal mineral of 
uroliths and urethral plugs in cats . 15 Struvite is 
magnesium ammonium phosphate hexahydrate (MgNH4Po4 ·6H20}. 
Microscopically, the crystals appear in cat urine as 
flattened prisms with variations in size and dimension 
(squares or rectangles) . Struvite crystals may develop a 
feathery appearance as they go i nto solution. 16 It has 
been suggested that the primary cause of FUS is the presence 
and effects of struvite calculi or crystals in the feline 
urinary tract . 17 It has been emphasized that detection of 
crystalluria is not synonymous with urolithiasis.16 Even 
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though FUS has heterogeneous causes, the one major factor in 
the syndrome is the formation of struvite 
calculi.1,2,3,18,19 
Struvite crystals are generally present in larger 
amounts in alkaline urine. 20121 •22 They are more soluble 
in acid urine and tend not to develop as urinary pH is 
reduced to below 6.6. 19120123 •24 The concentration of 
phosphate in the urine depends heavily on the pH, since as 
the pH increases, the phosphate concentration increases. 
Magnesium concentration increases by a lesser amount for a 
like pH change than does phosphate. An increase in ammonium 
ion concentration, which occurs as pH declines, decreases 
struvite solubility. Therefore, pH plays a dominant role in 
struvite crystallization. 25 Urinary pH increases 
postprandially, and it has been postulated that this 
fluctuation may be a triggering factor in cats which 
predisposes them to FUS . 26 The postprandial alkaline tide 
occurred specifically if the cats were fed once daily and not 
given food free choice throughout the day. 20 Another study 
demonstrated a postprandial rise in urinary pH occurred four 
hours subsequent to the resumption of feeding cats after a 
twenty-hour fast. The rise in pH occurred in cats on a dry 
diet with and without 1.6% ammonium chloride, which is a 
commonly used urinary acidifier in cats. The rise in pH did 
not occur in those cats being fed a moist diet.27 A study 
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that compared the effects of periodic and continuous feeding 
schedules determined that the cats fed periodically had their 
lowest urinary pH at the times the urinary mineral 
concentrations were the highest. This finding was thought to 
be a possible minor advantage of a morning periodic feeding 
schedule over continuous access to food. This study also 
examined the effects of diets with excessively high 
concentrations of magnesium and the relation of food 
accessibility to the incidence of urethral obstruction and 
found no difference to be associated with the feeding 
schedules. 28 
Diet as a primary factor in the etiology of FUS has been 
considered in recent years to involve only one constituent, 
dietary magnesium concentrations. The importance of dietary 
magnesium has been emphasized by several 
workers. 29 ' 30 ' 311 32 ' 33 ' 34 So called calculolytic 
diets, those low in magnesium, have been recommend from 
results of these types of studies for the treatment and 
prevention of FUs.18,35,36,37,38,39,40,41 It has 
been questioned whether the excessively high magnesium levels 
that were used in the experimental diets to cause 
urolithiasis are a representative model of naturally 
occurring cases of FUS. 1•42 The finding that addition of a 
urinary acidif ier to diets high in magnesium content 
inhibited urolith formation and caused dissolution of those 
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already formed has helped to put the effects of dietary 
magnesium in perspective . Concentrations of magnesium in the 
diet are important only if the urinary pH is in the alkaline 
range. 23143 Another study compared cats with experimentally 
produced urinary disease as a result of feeding high 
magnesium diets to those cats with natural occurring FUS. It 
was determined that undefined factors in addition to 
magnesium were involved in the natural disease. 44 Another 
study in cats concluded that fa c tors that affected urinary pH 
were more important than magnesium levels in the diet in the 
etiology of struvite crystalluria. 45 
Further, it has been demonstrated that the chemic al form 
in which magnesium is added to the diet had a direct 
influence on urinary pH . For example , magnesium chloride 
decreased urinary pH while magnesium oxi de produced an 
alkaline, calculogenic urine . It was concluded that FUS can 
be treated and prevented by urinary acidification, and that 
urinary pH was of primary importance in its pathogenesis. 
The formation of struvite urol iths is impossible and 
dissolution will occur at low urinary pH.46 ,47 
Recommendations have been made to use urinary ac i di f iers 
as part of the treatment regimen and as an aid in reducing 
the incidence of feline urologic s yndrome and its 
recurrence . 7 ' 17 ' 18 ' 23 ' 35 ' 37 ' 48 ' 49 ' 5° Caution has been 
advised against chronic over-acidification which could lead 
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to potential problems such as acidosis, potassium wasting, 
osteoporosis, and possible precipitation of non-struvite 
minerals. 47151 
Effects of Methionine in Animals 
A urinary acidifier that has been found effective is dl-
methionine. 7126135152 It has been found effective at a dose 
of 1000 to 1500 mg/day in preventing the postprandial 
alkaline urine production, 35137 and the higher dose was 
sufficient to dissolve struvite uroliths. 16 The urinary pH 
was effectively maintained at near 6.0 in one study by mixing 
dl-methionine in canned cat food that was fed for two hours a 
day to provide 1 . 5 grams daily intake. 53 Early workers 
believed that methionine was not an effective urinary 
acidifier even though it did prolong the time to urethral 
plugging in cats fed diets containing excessively high 
magnesium. 54 The perceived ineffectiveness of methionine 
as a urinary acidifier was because too low a dose was used in 
this study. An idea, that the sulfate produced from 
methionine may displace the phosphate in struvite thus 
preventing calculi formation, was proposed to account for the 
effectiveness of methionine in preventing urolithiasis when 
it was not thought to be a good urinary acidifier. 55 The 
activity of the components of struvite would be affected by 
the other ions that bind to them. It has been proposed that 
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less magnesium, ammonium, and phosphate would be available to 
precipitate as struvite when other ions are bound to 
them. 56 
Methionine has been found to be equally effective for 
acidification of urine as ammonium chloride when the two are 
compared on the basis of milliequivalents (mEq) of inorganic 
acid produced by each drug. This study demonstrated that to 
produce 5 mEq of acid, either hydrochloric acid produced from 
ammonium chloride or sulfuric acid produced from methionine, 
daily doses of 130-260 mg/kg of ammonium chloride or 185-370 
mg/kg of methionine would be required. This 5 mEq of acid 
produced was normally found to reduce feline urinary pH 
by 0.8 units. 52157 
Methionine loading in man led to an elevated rate of 
oxidation of the sulfur of methionine which resulted in 
increased rates of renal excretion of sulfate ion and non-
metabolizable acid. 58159 By varying the dietary content 
of sulfur the urinary output of acid was made to increase or 
decrease with the output of sulfate. 58 It has also been 
demonstrated in cats that dl-methionine decreased the urinary 
pH in essentially a linear dose response relationship when 
doses of 500, 1000, & 1500 mg were given. 52 After methionine 
loading in humans the excretion of net acid in urine rises 
gradually and levels off after two to three days. 59 It has 
been demonstrated in cats that stable urinary pH is reached 
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in approximately two days after dl-methionine treatment. 52 
The metabolism of methionine to sulfate yields two 
equivalents of hydrogen ion per mole of sulfur 
oxidized. 52 • 59 • 60 
Calcium methionine hydroxy analogue has been shown to be 
effective as an urinary acidifier in cats. 61 
A limited study in three cats on the effects of high 
doses of methionine (1 g/kg/day) found that increases in 
methemoglobin and Heinz bodies in erythrocytes occurred . At 
a dose of 0.5 g/kg/day in three other test cats recovery from 
the anemia started at seventeen to twenty-four days and was 
complete after fifty-two days even though methionine 
continued to be fed and methionine levels in plasma and red 
blood cells continued to increase. Adaptation to excess 
methionine intake apparently occurs in cats. 62 • 63 
Heinz bodies are denatured hemoglobin formed when 
irreversible oxidation of hemoglobin sulfhydryl groups 
occurs. 64 Cat red blood cells have at least eight reactive 
hemoglobin sulfhydryl groups, 65 making them more 
susceptible to oxidation and Heinz body formation than in 
other animals. 64 This oxidation process is reversed by a 
reducing system comprised of metabolically generated NADPH 
and glutathione present within the red blood cell. When 
extreme oxidative injury occurs red blood cells may lyse 
within the circulation. Red blood cells containing Heinz 
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bodies may be phagocytosed in the spleen or just the Heinz 
body and closely associated membrane may be removed. This 
removal is called the pitting function of the spleen. 66 
The cat spleen appears to have poor pitting capabilities, 
which may account for increased numbers of Heinz bodies in 
this species. 67 Most clinically normal cats have 
inclusions in their erythrocytes. These Heinz bodies have 
been considered physiologically normal and not related to any 
specific disease process. 68 A later study demonstrated a 
relationship between the presence of Heinz bodies and 
specific disease processes or metabolic alterations, and that 
endogenous Heinz bodies may contribute to anemia. There was 
a strong correlation of the diseases, diabetes mellitus, 
lymphoma, and hyperthyroidism with Heinz body formation. The 
suggestion was that the metabolic derangements that each of 
these conditions cause may provide the chemical initiators 
for Heinz body formation. Glutathione concentration was 
decreased in cats with Heinz bodies. Low degrees of 
oxidative stress to red blood cells may result in increased 
synthesis of glutathione as a protectant. 69 An early study 
indicated that formation of methemoglobin is an essential 
preliminary step in the oxidative degradation of hemoglobin 
and is also a precursor to the production of Heinz 
bodies . 70 The results of a later study suggested that the 
formation of methemoglobin and the production of Heinz bodies 
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are parallel processes, and methemoglobin is not a precursor 
of Heinz bodies. 71 Recently, it was found that unknown 
dietary factors have a role in the development of Heinz 
bodies in feline erythrocytes. These researchers suggested 
that the normal incidence of Heinz bodies in erythrocytes of 
healthy cats is an artifact caused by consumption of certain 
diets. It was also demonstrated in this study that propylene 
glycol induced Heinz body formation without an accompanying 
hemolytic anemia or methemoglobinemia. 72 
Circulating hemoglobin is principally in the form of 
oxygen-saturated hemoglobin (oxyhemoglobin) and nonoxygenated 
hemoglobin (reduced or deoxyhemoglobin) . The process where 
hemoglobin reversibly binds oxygen is called oxygenation 
which may be contrasted to the oxidation of hemoglobin where 
oxygen is tightly bound and unable to dissociate. The iron 
of the heme moiety of hemoglobin is oxidized from the 
bivalent ferrous to the trivalent ferric state, and 
hemoglobin is transformed into a brown pigment, 
methemoglobin . Methemoglobin is incapable of being 
oxygenated and is devoid of any respiratory function. 73 
This oxidation occurs stepwise, one iron at a time, and 
intermediate forms exist between hemoglobin and 
methemoglobin. 74 Methemoglobin disappears from the 
circulatory system within a few days after removal of the 
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causative oxidizing agent. Methemoglobin r e ducta se in normal 
red blood cells reconverts the methemoglobin to 
hemoglobin. 75 
A study in rats demonstrated adaptation to high dietary 
levels of methionine (3%) . The metabolic adaptation inv olved 
an increased ability of the animal to oxidize both the methyl 
and carboxyl carbons of methionine to co2 • It was also shown 
that the addition of either glycine or serine to the diets 
enhanced methionine metabolism only after the adaptation. 
These supplements were suggested to be beneficial in adapted 
animals via an enhanced rate of methi onine catabolism which 
resulted in lower blood conc entrations of methionine and 
increased food consumption and growth. 76 This adaption has 
been shown not to involve i nc reased cholin e synthesis as the 
method used by the rat to ox idatively metabolize the 
increased dietary methioni ne . 77 
Methionine has been characterized as one of the most 
toxic amino acids in a detailed r eview article. 78 The 
adverse effects due to excessive dietary concentrations 
appear to be due to an aberrant meta bolism of the methionine 
methyl group and its ultimate conversion to carbon dioxide. 
Various pathways may be invo l ved when different cellular 
concentrations of methionine are present. It was postulated 
that excess methionine ma y result in the production of methyl 
mercaptan (methanethi ol ) which may be toxic. 79 Methionine, 
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mercaptans, and increased blood ammonia among many other 
factors have been implicated as being involved in hepatic 
encephalopathy in the dog. 80 In healthy livers metabolites 
of methionine are converted to nontoxic substances . 81182 
In monkeys and dogs with surgically altered blood flow 
through the liver, plasma and cerebral spinal fluid (CSF) 
concentrations of methionine, cysteine, and ammonia were 
increased and signs of encephalopathy were evident. 
Neurological status improved and a decrease in plasma and CSF 
concentrations of methionine, cysteine, and taurine occurred 
when a parenteral solution low in methionine and aromatic 
amino acids and high in branched-chain amino acids was 
administered. 83 One passage through a normal liver removes 
virtually all of the ammonia that is received. Mammals can 
tolerate burdens of ammonia that are far in excess of those 
arising from normal metabolism. As previously noted the 
shunting of ammonia past the liver to the systemic 
circulation leads to neurological complications which have 
been reproduced by administration of ammonia or other 
nitrogenous substances. 84 Utilizing methionine hydroxy 
analogue as a urinary acidif ier may have an advantage 
compared to methionine in that MHA does not contribute to the 
body burden of ammonia, especially in those animals with 
impaired liver function. 
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A study in young rats had results that were consistent 
with the hypothesis that volatile sulfur compounds, such as 
methanethiol and hydrogen sulfide, cause methionine 
toxicosis. If these compounds are produced more rapidly than 
they are degraded, serious metabolic alterations may result. 
The oxidation of 3-methylthiopropionate, a product of the 
transamination pathway of methionine metabolism to sulfate 
increased as the rats increased in age. This difference 
between the ability to produce volatile sulfur compounds and 
to excrete them as sulfate may explain the toxicity of 
methionine in young animals. 85 A study in cats fed 
excessive methionine (1 g/kg) demonstrated increased plasma 
methionine but not 3-methylthiopropionate. 62 , 63 
The toxicity of methionine may vary with the species to 
which it is given . It has been shown that guinea pigs were 
much more sensitive than rats to the effects of 1-methionine. 
High dietary levels of 1-methionine (10 mrnol/kg/day) given to 
guinea pigs led to fatty liver, hypoglycemia, and 
aminoacidemia which was followed by hypothermia, profound 
hypoglycemia and death within 60 hours. Acute hepatic ATP 
deficiency (about 30 per cent of control values) was observed 
in all methionine-fed guinea pigs. None of the rats in this 
same study given this dose were ill by twenty-one days. 
There was no difference between the control and test rats in 
weight gain or blood sugar concentration. 86 Intramuscular 
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injections (60 mg/kg) in rabbits of 1-methionine, either once 
or daily for four days, resulted in hyperglycemia 
approximately 24 hours after the first injection with a 
return to normal after 72 hours in both groups. 87 
Growing kittens have been found to be more sensitive 
than young rats to excess methionine. The kittens in this 
study partially adapted to a 2.5% total daily intake of 
methionine (equivalent to 0.6 g/kg) after an initial 
reduction in food intake and weight gain. The kittens had a 
rectilinear weight gain by the end of the third week, and 
during the last ten days of this six week experiment the feed 
efficiency was about the same as that of the control 
group. 88 Another experiment in kittens fed purified diets 
demonstrated that purified diet containing 2 percent 
methionine severely depressed food intake and weight gain of 
female kittens, and after two months produced a dermatitis 
resembling feline acne. 8 9 This report did not include a 
description of the study or a tabulation of the results which 
limits its interpretat ion and value. 
A combination urinary acidif ier containing ammonium 
chloride and dl-methionine was fed at the rate of 0.45 grams 
of each drug to 3 kittens with a starting weight of 
approximately one pound . Death occurred in the 3 kittens at 
eleven (1) and fourteen (2) days preceded by sudden ataxia, 
depression, and coma. The plasma ammonia of one of the 
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kittens prior to death was reported to be 1334 µg/mL. Severe 
weight loss had occurred during the feeding period. Two 
control kittens from the same litter gained weight normally. 
Two other toxicoses in an eight and a nine week old kitten 
consuming this same combination of urinary acidif iers in a 
clinical situation was also described. 90 
A report describing a clinical case of Scotty cramp in a 
two-year old Scottish terrier was felt to have been induced 
by ingestion of approximately 9 grams of dl-methionine three 
hours prior to the onset. 91 The dog's weight was not given 
in this report. 
Methionine also has an effect on cardiac muscle. A 
study using 1-methionine perfusion of isolated hearts 
demonstrated that 1-methionine produced a biphasic effect in 
contractile function, initially negative inotropism followed 
by positive inotropism, which was associated with changes in 
membrane calcium transport due to phospholipid N-methyl-
ation. 92 Another study demonstrated that both phospholipid 
N-methylation and force development of cardiac contraction 
showed a dose-related dependence on methionine. 93 Whether 
excessive doses of methionine could produce detrimental 
effects on cardiac muscle in cats is unknown. 
Methionine has been shown to be required for maximum 
antibody response in broiler chicks, and the amount required 
was higher than that necessary for maximum growth. 94 
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Methionine loading (2.5 mmol/day) in weanling rats has 
led to a reduction in rate of food intake and body growth and 
to an extracellular hypochloremic acidosis subject to renal 
compensation. Balances of calcium and non-metabolizable base 
remained at normal values despite a decrease in whole blood 
"base excess.'' It was concluded that this acidosis was 
possibly due, not to retention of H+ released by ionization 
of endogenous sulfuric acid, but to the accumulation of 
organic acid metabolites of methionine with pKa values high 
enough to permit efficient renal conservation but low enough 
to cause the mild extracellular acidosis. 95 Another study 
in adult rats demonstrated a relationship between the level 
of sulfur amino acids in the diet and the excretion of 
calcium in the urine. Acid stress from the catabolism of the 
sulfur-containing amino acids can inhibit renal tubular 
reabsorption of calcium as can the complexing of the calcium 
with sulfate in the urine. 96 
Methionine administration in humans caused an acidosis 
which was associated with a moderate increase in 
inununoreactive parathyroid hormone (iPTH} and in urinary 
calcium excretion. No observations were made during the 
first six days of the administration, but by day seven the 
increases were fully established. No significant changes 
occurred in serum total calcium, ionized calcium, magnesium, 
phosphorus or in urinary phosphorus excretion. The results 
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obtained in another chronic treatment with ammonium chloride 
indicated that chronic acidosis elevated the iPTH mainly by 
producing hypercalciuria, and acidosis itself is not a 
primary stimulus to iPTH secretion. 97 
Another study in man demonstrated that administration of 
ammonium chloride produced mild metabolic acidosis without 
detectable changes in serum parathyroid hormone 
concentrations. Total serum calcium and magnesium 
concentrations decreased. A marked rise in daily urinary net 
acid and calcium excretion occurred. 98 
The long term use of urinary acidif iers in cats may 
affect the skeletal system if chronic metabolic acidosis 
develops. Bone dysfunction, which occurs most commonly in 
the young, has been associated with chronic metabolic 
acidosis. There is a delay in growth, presumably as a result 
of consumption of bone bicarbonate to buff er the excess 
hydrogen ion. Acidemia also causes an increased release of 
calcium phosphate from bone, with a reduced tubular 
reabsorption of these ions. This results in hypercalciuria 
and hyperphosphaturia directly proportional to the decrease 
in plasma bicarbonate concentration. 99 
Studies in the dog have suggested that in metabolic 
acidosis two separate phases of bone buffering occur. The 
first phase is thought to be a rapid, dynamic equilibrium 
that occurs within hours between the bicarbonate and hydrogen 
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ion of the extracellular fluid and the carbonate of the bone . 
This may be a surf ace phenomenon which is not dependent upon 
calcium mobilization s i nce no significant mobilization of 
calcium or phosphorus is noted during this phase. The second 
phase is a more long-term mobilization of carbonate from the 
bone that occurs over a period of days which is evident by 
mobilization of calcium and phosphorus associated with a 
lowering of extracellular bicarbonate. 100 
The oxidation of sulfur amino acids, such as methionine, 
coupled with ureagenesis tends to cause metabolic acidosis. 
Urea formation tends to decrease as severe acidosis occurs, 
and ammonia concentration tends to increase. If the ammonium 
ion produced is not properly eliminated, hyperammonemia could 
result. 10 1 The shift in nitrogen excretion from urea to 
ammonium in acidosis has been interpreted as a gain in 
bicarbonate since the latter is utilized in urea formation. 
Therefore, when waste nitrogen is excreted as ammonium, no 
bicarbonate is utilized and new bicarbonate, generated by the 
carbon skeleton, helps to maintain hydrogen ion 
homeostasis. 102 The traditional role ascribed to ammonia 
formation in the kidneys, which is to be utilized for the 
trapping of excess hydrogen ions for their excretion as 
ammonium, has been challenged by some scientists who 
concluded that the major reason for pumping protons is to 
trap ammonia . These researchers also believe that urea 
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synthesis is important more for utilization of bicarbonate 
and in blood pH regulation. Urea synthesis decreases during 
acidosis so that bicarbonate may increase. They further 
discuss that ammonium ion in the urine does not represent 
excretion of acid.lOJ,l04 , lOS This view has been 
challenged with the contention that the net effect of 
ureagenesis on acid-base balance should be nil since two 
ammonium ions are consumed for each bicarbonate 
ion.106,107 
The sulfuric acid produced from the oxidation of sulfur-
containing amino acids, such as methionine, is initially 
buffered in the extracellular fluid by bicarbonate. The 
carbon dioxide produced by this reaction is excreted by the 
lungs. Although the bicarbonate minimizes the increase in 
the hydrogen ion concentration, the excess hydrogen ions must 
be excreted by the kidney to prevent progressive depletion of 
bicarbonate and the other body buffers and severe metabolic 
acidemia. 
The kidney contributes to acid-base balance by 
regulating hydrogen ion excretion so that the plasma 
bicarbonate concentration remains within appropriate limits. 
The reabsorption of bicarbonate and the formation of 
titratable acidity and ammonium ion all occur by hydrogen ion 
secretion from the tubular cell into the lumen. 
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Since the urinary concentration of free hydrogen ion is 
extremely low, the net quantity of hydrogen ion excreted in 
the urine is equal to the amount excreted as titratable 
acidity and ammonium ion minus any hydrogen ion loss to the 
body because of urinary bicarbonate loss. 
Because of its favorable pKa (6.8) and relatively high 
concentration, the bulk of the urinary buffering is performed 
by monobasic phosphate. This process is referred to as 
titratable acidity since it is measured by the amount of NaOH 
that must be added to a 24-hour urine collection to titrate 
the urine pH back to pH 7.4, physiological pH. 
Since phosphate excretion does not increase markedly in 
the presence of an acid load, the ability to enhance net 
hydrogen ion excretion by increased formation of titratable 
acidity is limited. 
Ammonia (NH3) is a base which can combine with hydrogen 
ion to form ammonium (NH4+). The pKa of the NH3 /NH4 + system 
is 9.3 which makes this an ineffective buffer. Instead 
ammonia acts by passive, nonionic diffusion to allow hydrogen 
ions secreted into the lumen to be trapped as ammonium ions. 
Virtually all the ammonia in urine exists as ammonium. It is 
the continued diffusion of ammonia out of the cells that 
allows the NH3/NH4 + system to act as an effective ''buffer" 
even though its pKa is so far from urine pH. The ability to 
augment ammonia production and ammonium excretion is the main 
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adaptive response by the kidney to an acid load. Net acid 
excretion may be dramatically increased in metabolic 
acidosis. This is mostly due to enhanced ammonium excretion 
since titratable acidity is generally limited by the amount 
of phosphate in the urine. 108 
During acute acidosis, there is an increase in ammonia 
excretion that can be related simply to a change in urinary 
pH, without invoking a change in the actual rate of total 
ammonia production. During chronic acidosis, ammonia 
excretion is greater at any given pH compared to the 
controls . This adaptive increase in ammonia excretion is 
explained by an accelerated rate of ammonia production by the 
rena l tubule . 109 
The reactions which produce ammonia in renal tissue 
involve glutamine as the maj or precursor of the ammonia by 
giving up both of its nitrogens as ammonia in sequenti a l 
reactions. Intracellular c hanges resulting from acidosis 
account for increased tubul ar production of ammonia. The 
excretion of ammonia by mammals is primarily concerned with 
urinary excretion of non-volatile acid, not with elimination 
of waste nitrogen. 1 10 
Abnormalities of acid-base status can shift potassium 
into or out of cells and thereby alter plasma potassium 
concentration . In metabolic acidosis, a large proportion of 
the excess hydrogen ions are buffered intracellularly and as 
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hydrogen ions enter cells, potassium and sodium leave to 
maintain electroneutrality. The infusion of organic acids, 
such as lactic acid or keto acids, into animals caused a 
smaller increase in plasma potassium concentration than did 
mineral acids. 111 
The feeding of the free acid of MHA (MHA-FA) and 1-MET 
to chicks resulted in an acid-load that was manifested by a 
slight metabolic acidosis, which was greater in those chicks 
fed MHA-FA than those fed l-MET . 112,113 
Mature rats fed dl-methionine at a rate of 4.8% of their 
diet for a twenty day period demonstrated a depletion of fat 
stores and hypertrophy of the kidneys. 114 Excessive 
methionine, 2.5% and 4.5% of the total dietary intake, 
administered to rats for thirty days resulted in minor 
histopathological changes in the pancreas, gastrointestinal 
tract, salivary glands, kidneys, spleen, thymus, thyroid, and 
adrenal glands. It was also demonstrated in this study that 
the kidney weights in relationship to body weights were 
increased. Most of the changes could be attributed to the 
decrease in food intake, especially with the 4.5% methionine 
diet. 115 In addition, glycine and/or arginine added to the 
diets seemed to result in less extensive alterations 
histopathologically than when the methionine was supplemented 
alone. 116 
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Metabolism of Methionine 
Methionine is metabolized by a variety of reactions and 
pathways with many intermediates and products. Along with 
the toxicity problems of excess methionine many metabolites 
serve functions that are essential for survival of the 
organism. The sulfur amino acids have important catalytic 
roles in the active sites of many enzymes. Methionine is 
metabolized primarily to s-adenosylmethionine (AdoMet), a 
sulf onium compound that mediates most biochemical methylation 
reactions . It has been estimated that methyl transfer 
reactions as a group consume about 95% of the AdoMet formed. 
Homocysteine occupies a branch point in methionine 
metabolism . Approximately one-half of the homocysteine is 
irreversibly converted by trans-sulfuration to cysteine, 
alpha-ketobutyrate and ammonia. The remainder is 
remethylated to methionine. 117 Methionine alone can 
provide all the needed body sulfur compounds with the 
exception of the two vitamins containing sulfur, biotin and 
thiamine. Generally, methionine in the diet at twice the 
required level is well tolerated, but at a three-fold or 
above level toxicosis often results.118 
The other metabolic pathway that has been described for 
methionine degradation, the transamination-decarboxylation 
pathway, is independent of AdoMet formation. 119 The trans-
sulfurat i on pathway has been characteri zed as anabolic 
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metabolism in that diverse methylation products, such as 
phosphatidylcholine, epinephrine, and sarcosine are 
synthesized . The transamination pathway has been 
characterized as catabolic metabolism whereby excess dietary 
methionine is degraded for elimination. 120 It has been 
suggested that the transamination pathway operates when the 
capabilities of the trans-sulfuration pathway has been 
exceeded or impaired, and the intermediate, 3-methyl-
thiopropionate, in this pathway may be the source of 
methionine toxicosis. 121 This pathway is known to exist in 
the rat, monkey, pig, sheep, and probably other mammals . 122 
Adaptive increases in methionine oxidation have been 
demonstrated in both pathways in response to high levels of 
dietary methionine .123 
Methionine hydroxy analogue 
A study i n weanling and adult cats demonstrated that 
methionine is an indispensable ami no acid, and that ca l cium 
MHA was not utilized well as a source of methionine when the 
cats were fed a crystalline amino acid diet. MHA was shown 
to be well utilized as a source of methionine when the diet 
was a semi-purified one providing amino acids from intact 
protein in the form of soybean meal.124 
The total sulfur amino acid requirement of growing 
kittens is approximately 0. 9 percent of the diet with the 
minimal methionine contribution being between 0.3 and 0.45 
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percent . 12 5 ,126 When the diet of cats consists of a high 
amount of animal protein the substantial amounts of sulfur 
amino acids present (methionine, cystine) are oxidized to 
sulfate and contribute to urinary acidification . Veget able 
protein and low-protein diets tend to be low in sulfur amino 
acids and high in potassium and magnesium resulting in more 
alkaline urine and struvite precipitation. 7 
Methionine hydroxy analogue has also been found to be 
effective in replacing the 1-methionine requirement in the 
diet of growing dogs. 127 
Complete substitution or replacement of dl-methionine in 
the diet of rats by CaMHA has been made wi t h out effect on 
growth or feed efficiency. Also noted was a n increase in 
urea clearance in the groups fed the hydroxy analogues. 128 
An experiment in rats, studying the improvement of the 
protein value of soya, included supplementation of the soya 
protein with 1-MET or dl-MHA. Both MET and MHA were 
maximally efficient in elevating the biological value of the 
soya protein at a 1 percent concentration . When the 
supplementation exceeded 18 percent, similar toxic effects of 
reduced food intake and deterioration of general health were 
noted with both MHA and MET. The toxic effects were 
characterized to be similar but were less drastic with MHA 
than with MET. This difference in degree of severity was 
accounted for by the absence of the dilution of the 
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assimilable protein nitrogen fraction when MHA was used 
instead of MET. The toxicoses of the amino acid or hydroxy 
analogue excesses caused anorexia resulting in tissue 
breakdown which resulted in increased urinary nitrogen, and 
thus an apparent decrease of biological value of the protein 
as the amount of MET and MHA were increased in the diet. 129 
The conversion of MHA into MET was shown to be 
accomplished via a ketomethionine intermediate involving an 
enzyme-dependent oxidation reaction. The ultimate conversion 
of the ketomethionine to 1-methionine was accomplished 
through a transamination reaction involving various donor 
amino acids in the chick130 • 131 and the rat. 132 The 
rat study demonstrated that kidney contained the greatest 
amount of activity per gram of tissue, but the liver, because 
of its greater size, played a predominant role in converting 
MHA into MET in the intact animal. The chick studies also 
demonstrated that the renal threshold for dl-MHA was 
equivalent to that for 1-MET, and that they both appeared to 
be reabsorbed against concentration gradients. Dietary 
equivalence of MHA and MET was shown in both studies . Later 
studies revealed stereospecif ic different enzymes involved in 
the oxidation of the d- and 1- isomers of MHA to keto-
methionine prior to the transamination reaction. 133 The 
transamination reaction of ketomethionine to 1-MET is 
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reversible and may proceed to the transamination degradation 
pathway from the ketomethionine as was discussed earlier. 
A study in chicks fed a crystalline amino acid diet 
demonstrated that the calcium salt of ketoMET was less 
efficacious than dl-MET, but more efficacious than CaMHA. 
The implication was that conversion is not 100 percent 
efficient . MHA was characterized as considerably less toxic 
than an equimolar quantity of MET. 134 
Another study showed that CaMHA was slightly inferior to 
dl-MET in feed conversion efficiency in layer hens. The free 
acid form of MHA (MHA-FA) in diets caused distinctly inferior 
performance of hens to that of birds fed dl-MET . 135 In 
attempts to characterize and define the reasons for inferior 
performance of MHA-FA, excretion studies determined that 1-
MET was the major excretion product of both MHA-FA and 1-MET, 
and that MHA-FA is not actively excreted by the avian 
kidney.112,113 
Another comparison of the metabolism of MHA and MET 
demonstrated no differences in the oxidation of the 1-MET, 
dl-MET, and dl-MHA in young growing day old broilers, but the 
amount of dl-MHA in the excreta was significantly greater 
compared to the other two sources. 136 
A study in three week old pigs showed that the 
methionine requirement can be satisfied with either 1-MET, 
dl-MET, or dl-MHA at a level equal to 0 . 51 percent of the 
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dietary solids in a liquid feeding system. It was apparent 
that MHA was converted to MET since the plasma MET 
concentration increased significantly with increment 
increases in concentration of dietary MHA. This test 
demonstrated that a decrease in plasma urea occurred when MHA 
or MET was added to a diet deficient in sulfur-bearing amino 
acids. It was determined that the amount of dietary MET 
required to support maximum growth is greater than that which 
is required for maintaining nitrogen balance since MET is an 
amino acid that has many functions other than protein 
synthesis. The safety margin was narrow between optimum 
growth and toxicosis . 137 
CaMHA used as the methionine source in rainbow trout 
resulted in lower growth rates than when the source was 
either 1-MET or dl-MET. Higher dietary levels of CaMHA were 
required to prevent cataracts in the fish than MET. 138 
A study of kidney fibroblast growth found that dl-MHA 
could be utilized as a source of MET, but the efficiency was 
dependent on the presence of a basal amount of MET. Higher 
concentrations of MHA than MET were required. 1-MET had a 
lower margin of safety compared to dl-MH.A. 139 
In vitro studies in rats have demonstrated that jejunal 
uptake of MHA is mediated by a Na+-independent carrier system 
associated with lactate transport and is distinct from the 
methionine uptake mechanism which is Na+-dependent. MHA was 
31 
found to be more slowly absorbed than methionine. It was 
postulated that this difference could explain the lower 
biological utilization of MHA as the sole source of 
methionine in purified crystalline amino acid diets. 140 
However, this is contrasted to the finding in chickens that 
passive diffusion is the mechanism of MHA absorption . In 
this study the uptake of CaMHA was less than half that of 
dl-methionine. 141 Other in vitro studies in chicks found 
that MHA uptake was linear in relation to concentration and 
methionine was absorbed by both concentration and energy 
dependent processes . The results indicated that MHA as a 
substitute for methionine would not be limited by 
absorption. 142 These absorption d ifferences may be due 
partially to different experimental designs in these studies. 
It is not known whether absorption of increased levels of MHA 
or methionine is a factor i n their comparative performance in 
cats. 
Another transport system for MHA is involved in the 
growth in tissue culture of porcine kidney fibroblasts. 
Although the d- and 1- isomers of MHA are oxidized by 
different enzymes, the conversion rates to the alpha keto 
methionine are similar. However , the d- isomer of MHA 
promoted the growth of the fibroblasts while the 1-MHA did 
not when each was used as the sole source of methionine. It 
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appeared that a stereospecif ic transport system was present 
which permitted d-MHA to be moved into the cell but not 
l-MHA.143 
MHA, because it does not add to the dietary nitrogen 
content, has been used in protein evaluation trials to 
replace MET in "protein-free" diets to effectively reduce the 
time required for stabilization of the endogenous urinary 
nitrogen output in young rats. 144 
In adult humans in renal failure, where maintenance, not 
growth, is the goal, the use of keto and hydroxy acids in 
replacement of amino acids makes the goal more 
attainable. 145 Nitrogen-free analogues of essential amino 
acids given as supplements to a low protein diet in humans 
have been shown to be nitrogen sparing. This treatment 
regime for chronic renal disease is only useful when dietary 
protein is restricted. When the protein is high in a diet 
these amino acid analogues are rapidly degraded. 146 •147 
Model systems to assess bioequivalence of different 
methionine sources have included nonpurified diets, purified 
diets, crystalline amino acid diets, and cell cultures. 
Therefore, the many studies comparing MHA and MET have 
contradictory results attributable to differences in basal 
methionine concentrations, whether cystine is in the diet and 
at what concentration and ratio to methionine, the age and 
species of animal tested, and how much choline or lecithin is 
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provided in the diet . The toxicity of methionine has been 
found to be at concentrations slightly above those 
concentrations which allow a maximum feed gain response. 139 
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MATERIALS AND METHODS 
Test Drugs 
The test drugs were manufactured and provided by 
Vet-A-Mix Animal Health, Inc., 604 West Thomas Avenue, 
Shenandoah, Iowa.a The dosage forms were manufactured under 
the Current Good Manufacturing Practice (GMP) 
regulations. 148 The two drugs that were used in this 
study, dl- methionineb and calcium methionine hydroxy 
analoguec were formulated into compressed tablets in a 
palatable base. Dosages were formulated based on the 
theoretical amount of sulfuric acid produced by the 
metabolism of each compound . 149 Each MET tablet contained 
75 mg of methionine which is equal to one milliequivalent of 
sulfuric acid produced. Each MHA tablet contained 85 mg of 
calcium methionine hydroxy analogue which is equal to one 
milliequivalent of sulfuric acid produced . 
The chemical formula for calcium methionine hydroxy 
analogue is (CH3S(CH2 ) 2CHOHC00) 2Ca, and for dl-methionine the 
chemical formula is CH3S(CH2 ) 2CHNH2COOH. 
asponsor of the research study 
IA. 
bMethio-Form™, Vet-A-Mix Animal Health, Inc. , Shenandoah, 
cinvestigational New Animal Drug #6460, Vet-A-Mix Animal 
Health, Inc., Shenandoah, IA. 
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Test Animals 
The test system was 42 healthy mature cats which were at 
least 6 months of age. There were equal numbers of males and 
females. The weight range was 2.5 to 5 . 3 kilograms. The 
cats were random-source animals which had been acquired and 
conditioned (which included vaccination, worming, and an 
isolation period to assure health) by Laboratory Animal 
Resources, Iowa State University, Ames, Iowa . During the 
study they were housed in individual stainless steel cages 
with water and food available ad libitum . Each cat was 
permanently identified by a tattoo on the inner surface of 
the pinna of the ear . 
Test Di e t 
Purina Cat Chowd was c hosen as the test diet because it 
did not contain any adde d dl-methionine . One manufacturing 
lot number of food was used for the entire study. The food 
was provided free choice to the cats, instead of providing 
the food for a limited time period or on a meal basis, so 
that individual eating habits would not affect intake. 
Analysis of the food was c onduc ted for presence of free 
methionine by the sponsor of the study and none was detect ed. 
dLot #3D10 7R, Ralston Purina Company, St . Louis, MO. 
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Test Groups 
The study was divided into 3 replications of 14 cats 
each, which were randomly assigned to 7 treatment groups with 
one male and one female in each group per replication. The 
two treatments, MHA and MET, were given at 3 different levels 
(low, medium, and high). The control group had no treatment 
applied. The low dose was approximately the normal dose of 
dl-methionine that is recommended to be given daily in a 
clinical situation, and the medium dose was considered the 
high end of the normal dose range.e Equivalent amounts of 
the two test drugs were given at each level. The result 
was 7 test groups , each having a total 6 cats, 3 of which 
were females and 3 of which were males, with an overall tota l 
of 42 cats . The test groups are summarized below. 
Dose 
Grou12s Treatment Level (mEgLkg) 
1 CONTROL none 0 
2 MHA low 2.5 
3 MHA medium 5 . 0 
4 MHA high 10 .0 
5 MET low 2.5 
6 MET medium 5 . 0 
7 MET high 10.0 
el988-89 Product Catalog, Vet-A-Mix Animal Health, Inc . , 
Shenandoah, IA. 
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Test Design 
The study was conducted to comply with current Good 
Laboratory Practices (GLP) . 150 
The testing procedures were begun after the cats had 
been acclimated to the basal diet and housing for 14 days. 
The test medication was administered once a day at the same 
time each morning and was given for 7 days. The cats were 
observed for 7 days after the dosing was stopped. 
Sample Collection 
Sample collection was started after the 14 day 
acclimation period and was made 5 times: two times prior to 
treatment to establish baselines, two times during the actual 
dosing, and one time seven days after the last dose was 
given . The last sample collection was made to determine 
whether the parameters examined had returned to normal by the 
end of the trial . The sample collection times are summarized 
as follows: 
Sample Time 
1. -3 day (3 days prior to the 1st dose) 
2 . 0 day (just prior to the 1st dose) 
3 . +3 day (24 hours after the 3rd dose) 
4. +7 day (24 hours after the 7th dose) 
5. +14 day (7 days after last dose) 
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Samp l es, uri ne 
The cats were monitored for the entire 24 hour urine 
collection period to prevent fecal contamination and to 
assure fresh urine samples. During each of the c o llection 
periods, urine was collected from each cat by allowing it to 
urinate through the grates of its cage into the collecting 
tray beneath. Prior to the start of the c o llection period, 
the cage grates and trays beneath were thoroughly washed and 
rinsed several times with distilled water, dried and 
replaced. This was to provide uncontaminated samples. After 
each time the cats defecated or urinated, the trays were 
rewashed, rinsed and dried . The samples were drawn from the 
trays with syringes, the volumes determined, and the urine 
placed in glass containers containing toluene as a 
preservative. They were kept in an ice water bath until 
analyses were done. At the end of each collection period 
distilled water was sprayed through the floor grates into 
three different cage trays . This water was collected from 
the trays in a similar manner as the urine. These water 
samples were found to contain only an occasional trace of 
ammonia, thereby insuring that the ammonia found came from 
t he urine. 
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samples, jugular blood 
A total of 6 mL of blood was drawn from each cat at each 
collection. Glass syringes and needles were filled with 
heparin, which was expelled prior to collecting blood for 
blood gas analyses and methemoglobin determinations. Sterile 
blood collecting vacuum tubesf containing potassium EDTA as 
an anticoagulant were used to collect blood for the 
hematology and ammonia determinations. Untreated sterile 
blood collecting vacuum tubesf were utilized to collect blood 
samples to determine electrolytes, urea nitrogen, creatinine, 
liver enzymes, and glucose values . All samples were placed 
in an ice water bath as soon as they were collected and kept 
there until analysis. The samples for blood gas measurements 
were submitted for analyses as soon as every four samples 
were collected or approximately every 30 minutes. The serum 
samples were submitted at the end of the blood collection 
time (1.5-2 hours). The procedures to determine blood 
ammonia concentrations were begun after the final blood 
sample was drawn. The hematologic tests were conducted 
approximately 2.5-3.5 hours aft er the last sample was taken. 
Samples, necropsy 
A complete necropsy was performed on 6 cats in the first 
replication: 2 control cats from group one, 2 high dose MHA 
fsherwood Medical, st. Louis, MO. 
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cats from group four, and 2 high dose MET cats from group 
seven. A complete necropsy was performed on 10 cats in the 
second replication: 2 control cats from group one, 2 medium 
MHA cats from group three, 2 high MHA cats from group four, 2 
medium MET cats from group six, and 2 high MET cats from 
group seven. Two of the cats died in the first replication, 
one from group four and one from group seven. Necropsies 
were performed on these two animals approximately one hour 
and three hours, respectively, after their deaths. 
Euthanasia was accomplished by lethal injectiong into a 
jugular vein of each of the remaining cats, and they were 
necropsied within 30 minutes of the time of death . Tissues 
were observed grossly and sections of the t i ssues were fixed 
in buffered-neutral formalin for histopathologic examination. 
The tissues collected included: liver, kidney, spleen, 
adrenal, brain, duodenum, pancreas, heart, and urinary 
bladder . 
Test Parameters 
Food intake 
The food was fed ad libitum . The cats were fed twice 
daily as the bowls did not have enough capacity for the 24 
hour needs for some of the larger cats . The 24 hour feed 
consumption for the entire length of study was determined by 
gSleepaway, Ft. Dodge Laboratory, Ft. Dodge, IA. 
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weighing the food that was not consumed each morning and 
calculating the intake for the previous day . The food was 
weighed on a triple beam balanceh that was routinely 
validated and calibrated by using class M-2 traceable 
weight s.i 
Body wei ght 
The cats were weighed at each sampling day just prior to 
blood collection. The animals were weighed on a small 
platform scalej that was validated to be accurate prior to 
each replication . 
Gener a l observat i ons 
The test subjects were observed twice daily before and 
after the dosing period. During the urine collections, the 
cats were monitored continuously for 2 4 hours. On the other 
treatment days the animals were checked frequently during 
each day . 
hohaus Scale Corporation, Florham Park, NJ. 
ioenver Instrument Company, Arvada, co. 
jModel 2020, Toledo Scale Company, Toledo, OH. 
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Urine 
The parameters that were measured in the urine included 
the following: 
pH 
Titratable acidity to pH 7 .4 and 8.4 
Ammonia 
Electrolytes: Magnesium, Phosphorus, Calcium 
Volume 
Creatinine 
Urea nitrogen 
Specific gravity 
Urine volume was determined as each voided sample was 
collected during the 24 hour collection period. After the 
collection period approximately 4 mL was submitted for 
measurement of magnesium, phosphorus, calcium, creatinine, 
and urea nitrogen on an automated instrumentk by standard 
methods of the Clinical Pathology Laboratory of the College 
of Veterinary Medicine at Iowa State University. A 20 mL 
sample was transferred from beneath the toluene preservative 
and allowed to come to room temperature. The pH was 
determined with a pH meter . 1 The pH electrode was rinsed 
kAbbott Spectrum, Dallas , TX . 
1Model #16087, Markson pH Meter, Phoenix, AZ. 
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with distilled water and calibrated with a 7.0 pH standard 
buffer between each sample. The sample was titrated to two 
end points, 7.4 and 8.4, with 0.075N NaOH, and the titratable 
acidity in the twenty-four sample was calculated. 
The ammonia was determined on a 0.5 mL sample from the 
initial specimen by the Modified Conway Method. 151 This 
microdiffusion method of ammonia determination involved the 
gaseous diffusion of ammonia from the outer chamber of the 
Conway dish after the sample was mixed and incubated with a 
releasing buffer. The ammonia that diffused into the inner 
trapping and indicator chamber was quantitated by titrating 
with dilute sulfuric acid from a micropipette. The specific 
gravity of the urine was measured with a total solids meterm 
according to the standard methods of the Clinical Pathology 
Laboratory, College of Veterinary Medicine, Iowa state 
University. 
mA.merican Optical, Buffalo, NY. 
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Blood 
were: 
The measurements made either on blood, serum, or plasma 
pH 
Bicarbonate 
Red blood cell count 
Packed cell volume 
Hemoglobin 
Urea nitrogen 
Creatinine 
Alkaline phosphatase 
Alanine aminotransferase 
Glucose 
Ammonia 
Electrolytes 
Sodium 
Potassium 
Chloride 
Calcium 
Phosphorus 
Magnesium 
Heinz body formation 
Methemoglobin 
The blood pH and bicarbonate concentrations were 
determined on a blood gas machine. 0 An automated 
hematologic analyzer0 was used to determine the red cell 
count, packed cell volume, and hemoglobin. The Heinz body 
counts were made from blood smears that had been stained with 
new methylene blue supravital stain. 651152 The r -emaining 
measurements, with the exception of methemoglobin and 
0 Radiometer, ABL 3, Copenhagen, Denmark. 
0 coulter Electronics, Inc., Hialeah, FL. 
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ammonia, were made on an automated instrumentP. The 
preceding procedures were all performed according to the 
standard methods of the Clinical Pathology Laboratory, 
College of Veterinary Medicine, Iowa State University. The 
Heinz bodies in 1000 red blood cells were counted under oil 
emersion at lOOOX. Methemoglobin levels were determinedq 
from fourteen cats from the third replication at time four (7 
days after treatment) by the classic method. 153 The 
ammonia nitrogen concentration of the blood was determined by 
the Modified Conway Method151 similar to the procedure 
performed on the urine . 
Hi stopathol oqy 
Tissues were processed,r embedded i n paraffin blocks, 
and sectioned to a thickness of five microns and stained with 
hematoxylin and eosin. All tissues collected were examined 
from the animals necropsied in the first replication. Only 
the liver and kidney were examined histologically in the 
second replication. The liver and kidney in the second 
replication in addition to hematoxylin and eosin were also 
PAbbott Spectrum, Dallas, TX. 
qProcedure No. 8268, Mayo Medical Laboratories, Rochester, 
MN. 
rHistomatic MVP, Fisher Scientific, Pittsburgh, PA. 
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stained with PAS (Periodic Acid-Schiff) with diastase 
digestion of glycogen to confirm the presence of 
glycogen. 154 
Test Statis tics 
Statistical analyses were perf ormed9 using all test 
parameters as variables. Collection times one and two were 
merged into one baseline sample time for purpose of analyses. 
Initially, the effects of replication, treatment, sex, 
replication*treatment, and sex*treatment were examined at 
each sample time. Replication*treatment was used as the 
error term to compare treatments using the analysis of 
variance (ANOVA) procedures . Further analyses were conducted 
on variables that demonstrated significant differences among 
treatment groups at P <0 . 05 level . These additional 
analyses consisted of comparing the control group t o the 
other six treatment groups and the three MHA groups to the 
three MET groups . Also, linear and quadratic models were 
applied to the three MHA groups and to the three MET groups. 
9 General Linear Models Procedure, Statistical Analysis 
Systems, SAS , Inc., Cary, NC . 
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RESULTS AND DISCUSSION 
The results and discussion are divided into two main 
sections; those test measurements which did not demonstrate 
differences among the treatment groups, and those test values 
which did demonstrate differences among the ·treatment groups . 
There are a few minor exceptions to this general subdivision 
with some of the parameters measured. The exceptions 
primarily involved situations where statistical differences 
could not be related to treatments or could not be related to 
values outside those considered to be normal . 
In general, the baseline sample time, whi ch is pre-
treatment collection Time 1 and Time 2 averaged i nto one 
value, shows no significant d i fferences among groups, as 
would be expected, since no treatments were applied at these 
times . The collection Time 5 , which was seven days after the 
last treatment, also showed no s i gnifi cant differences 
between groups for most measurements. Specific instances in 
which differences between groups persisted into the recovery 
period are referred to when the individual variables are 
discussed . 
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Parameters wi th Chang e s Presumed Not t o be Treatment Re l ated 
The test parameters that appeared not to be altered by 
the treatments included the following: 
Body weight 
Urine 
Blood 
Necropsy 
Calcium, Creatinine, Specific gravity. 
Red blood cell count, Packed cell volume, 
Hemoglobin, Methemoglobin, Alkaline 
phosphatase, Alanine aminotransferase, 
Glucose, Sodium, Chloride, Calcium, 
Magnesium, Ammonia, pH, pco2 • 
Histopathology 
The numerical mean values for these parameters are 
listed in Tables 1-16 with a short discussion preceding each 
one. The standard error of means, F-value, and probability 
of significance are given at each time period. 
Body wei ght 
The average body weight among groups was not 
significantly affected at any of the sample times. This 
occurred even though food consumption was significantly 
reduced . The short treatment period for this test did not 
allow time for the effects of treatments to be manifested in 
weight loss. The cats in this test were mature instead of 
growing cats which also helps to account for no effect on 
49 
body weight over the period of the test. The results of 
these comparisons are provided in Table 1. 
Table 1. Body weight means in kilograms, standard error of 
means, F-values, and probabilities of significance 
for treatment groups prior to treatment (baseline) , 
during treatment (time 3 and 4), and after 
treatment (time 5) 
Level of 
Group Treatment 
1 None-Control 
2 Low MHA 
3 Med MHA 
4 High MHA 
5 Low MET 
6 Med MET 
7 High MET 
Standard Error of 
Means 
F-Value 
Pr > F 
urinary calcium 
Baseline 
Time 
1, 2 
3.67 
3 . 89 
3 . 72 
3 . 87 
3.66 
4.27 
3.97 
0.55 
0 . 74 
0.6276 
Time 
3 
3.66 
3.87 
3.77 
3 . 79 
3.67 
4.14 
3.87 
0.55 
0 . 43 
0.8474 
Time 
4 
3.66 
3.89 
3.73 
3.70 
3.78 
4 .12 
3.73 
0.56 
0.37 
0 . 8817 
Time 
5 
3.72 
4.00 
3.87 
3 .63 
3.91 
4.17 
3.90 
0.56 
0.44 
0.8398 
Hypercalciuria did not occur in any of the groups during 
the treatment phase of the study . There was no correlation 
between the metabolic acidosis that some of the treatment 
groups developed and calcium excretion. The increased 
calcium excretion that can occur with acute and chronic 
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metabolic acidosis , which was described in the literature 
review, was not evident in this study. Apparently, the seven 
day treatment period did not result in loss of calcium from 
the skeleton to provide carbonate for buffering purposes of 
the metabolic acidosis that occurred. The increases of 
calcium excretion that were noted in some groups during 
treatment were not significant as can be seen in Table 2. 
Table 2. Urinary calcium means in mg/dl, standard error of 
means, F-values, and probabilities of significance 
for treatment groups prior to treatment (baseline), 
during treatment (time 3 and 4), and after 
treatment (time 5) 
Group 
1 
2 
3 
4 
5 
6 
7 
Standard 
F-Value 
Pr > F 
Level of 
Treatment 
None-Control 
Low MHA 
Med MHA 
High MHA 
Low MET 
Med MET 
High MET 
Error of 
Means 
Baseline 
Time 
1, 2 
0 . 292 
0.258 
0.29 2 
0.225 
0 . 308 
0 . 258 
0.325 
0 . 032 
1.16 
0.3871 
Time 
3 
0 . 217 
0.467 
0.650 
0 . 300 
0.500 
0 . 533 
0 . 500 
0.102 
2 . 07 
0.1333 
Time 
4 
0.300 
0.350 
0. 3 6 7 
0.567 
0 . 350 
0.417 
0.425 
0.099 
0. 7 3 
0.6347 
Time 
5 
0 . 240 
0.200 
0.300 
0 . 275 
0.300 
0 . 200 
0 . 200 
0.032 
1. 76 
0 . 2149 
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Urinary creatinine 
The urinary creatinine excretion values were not 
significantly altered except seven days after the last 
t r eat ment at Time 5. The differences at Time 5 cou ld not be 
relat ed to any particular treatment group. The values are 
tabulated in Table 3. 
Table 3. Urinary creatinine means in mg/dl, standard error 
of means , F-values, and probabilities of 
significance for treatment groups prior to 
treatment (baseline), during treatment (time 3 and 
4), and after treatment (time 5) 
Group 
1 
2 
3 
4 
5 
6 
7 
Standard 
F-Value 
Pr > F 
Level of 
Treat ment 
None-Control 
Low MHA 
Med MHA 
High MHA 
Low MET 
Med MET 
High MET 
Error of 
Means 
Urine specif i c gravity 
Baseline 
Time 
1, 2 
318 
341 
310 
292 
348 
328 
316 
22 
0.73 
0.6325 
Time 
3 
317 
358 
288 
236 
319 
292 
254 
24 
2.93 
0.0536 
Time 
4 
316 
342 
285 
272 
279 
328 
257 
20 
2.36 
0.0964 
Time 
5 
297 
340 
305 
256 
278 
337 
330 
12 
6.16 
0.0038 
The mean specific gravity of the urine was generally 
high for all groups at all collection times. The range was 
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from 1.051 to 1.061. The cat is capable of producing very 
concentrated urine as the animals in this study demonstrated. 
The significant difference among groups at Time 3 was not 
considered to be a clinically significant finding since the 
values were not outside normal ranges, the change did not 
persist at Time 4, and the change could not be linked to any 
particular treatment . The specific gravity values are given 
in Table 4. 
Table 4. Urine specific gravity means, standard error of 
means, F-values, and probabilities of significance 
for treatment groups prior to treatment (baseline) , 
during treatment (time 3 and 4), and after 
treatment (time 5) 
Group 
1 
2 
3 
4 
5 
6 
7 
Standard 
F-Value 
Pr > F 
Level of 
Treatment 
None-Control 
Low MHA 
Med MHA 
High MHA 
Low MET 
Med MET 
High MET 
Error of 
Means 
Baseline 
Time 
1, 2 
1. 056 
1. 058 
1. 060 
1 . 056 
1. 059 
1. 059 
1.059 
0.002 
0 . 92 
0 . 5139 
Time 
3 
1. 051 
1.059 
1.059 
1. 048 
1.058 
1. 053 
1.053 
0.002 
4.73 
0.0107 
Time 
4 
1.055 
1.063 
1 . 063 
1.056 
1.058 
1.062 
1.057 
0.003 
1. 09 
0.4224 
Time 
5 
1.052 
1. 059 
1.061 
1. 054 
1. 061 
1.059 
1. 061 
0.003 
1. 54 
0.2478 
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Red b l ood cell c ou nt 
The red blood cell counts demonstrate that no effects 
can be attributed to treatments applied for the seven day 
period as far as any erythrocyte destruction is concerned. 
Time 5 approached significance, P <0.0510. Group 7, high MET 
treatment, showed the greatest reduction in RBC count 
compared to the other groups at this time. The possibility 
that a clinical anemia could have developed with continued 
treatment exists, but the RBC count in Group 7 was still well 
within normal values. The values may be compared in Table 5. 
Table 5. Red blood cell count means in million/µl, standard 
error of means, F-values, and probabilities of 
significance for treatment groups prior to 
treatment (baseline), during treatment (time 3 
and 4), and after treatment (time 5) 
Baseline 
Level of Time Time Time Time 
Group Treatment 1, 2 3 4 5 
1 None-Control 8.480 7 . 690 8.003 8.080 
2 Low MHA 6.691 6.375 8.018 7 .515 
3 Med MHA 7 . 896 7 . 403 7 .52 7 7 . 532 
4 High MHA 7 . 886 6.432 7.457 6 . 752 
5 Low MET 7 . 434 7.373 7.362 7.713 
6 Med MET 7 . 311 6.987 7 .225 7 . 340 
7 High MET 7.253 7 .490 7.816 6.236 
Standard Error of 0.606 0.782 0.414 0.369 
Means 
F-Value 0 . 84 .045 0.58 2 . 98 
Pr > F 0.5610 0.8316 0 . 7418 0.0510 
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Packed cel l v olume 
This hematologic parameter was not significantly altered 
at any of the sample times by any treatments. Again, Group 7 
had the lowest PCV which is consistent with the lower 
erythrocyte count in this group at this collection time. The 
PCV was at the low end of the normal range at this 
collection. Packed cell volumes are given in Table 6. 
Table 6. Packed cell volume means in %, standard error of 
means, F-values, and probabilities of significance 
for treatment groups prior to treatment (baseline), 
during treatment (time 3 and 4), and after 
treatment (time 5) 
Baseline 
Level of Time Time Time Time 
Group Treatment 1, 2 3 4 5 
1 None-Control 37.8 35.2 35.5 37.3 
2 Low MHA 39 .4 35.2 34.0 33.7 
3 Med MHA 35.4 33.8 33 . 0 34.2 
4 High MHA 35. 6 36 . 2 34.3 32.4 
5 Low MET 36.5 33.2 33.0 35. 3 
6 Med MET 33.1 32.7 33.3 34.5 
7 High MET 37.2 34.8 36 . 0 30.4 
Standard Error of 1.96 1. 77 1. 73 1. 67 
Means 
F-Value 0.94 0.50 0 .42 1. 83 
Pr > F 0 . 991 0 . 7995 0.8543 0.1760 
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Hemoglobin 
Hemoglobin values were not altered. The inter-
relationships of the three hematologic parameters, PCV, RBC 
count, and hemoglobin, as measured by mean cell volume (MCV), 
mean cell hemoglobin concentration (MCHC), and mean cell 
hemoglobin (MCH) were also calculated and each were found not 
to be different among groups. The hematologic parameters 
measured give no evidence of a hemolytic anemia occurring as 
a result of the treatments. The hemoglobin values are 
compared in Table 7 . 
Table 7. Hemoglobin means in g/dl, standard error of means, 
F-values, and probabilities of significance for 
treatment groups prior to treatment (baseline) , 
during treatment (time 3 and 4), and after 
treatment (time 5) 
Baseline 
Level of Time Time Time Time 
Group Treatment 1, 2 3 4 5 
1 None-Control 12.5 11. 5 12.0 12.2 
2 Low MHA 12.9 11. 6 11.4 11.1 
3 Med MHA 11. 7 11.1 11 .2 11. 3 
4 High MHA 11. 7 12.0 12.2 10 . 8 
5 Low MET 12.1 10.8 11. 0 11. 6 
6 Med MET 10.8 10.6 11. 0 11. 2 
7 High MET 12.3 11. 4 12.8 10.4 
Standard Error of 0 .75 0.68 0.72 0.60 
Means 
F-Value 0.77 0.56 0.82 0 .99 
Pr > F 0.6085 0.7572 0 . 5743 0 . 4744 
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Methemoqlobin 
A problem in the laboratory prevented conducting this 
test at all collection times. The only time values were 
determined was on the last replication after fourteen cats 
had been given the treatments for seven days. The average 
methemoglobin percent of total hemoglobin for two cats by 
group did not demonstrate apparent differences between groups 
(Group 1=1 .05 %, Group 2=1.05%, Group 3=1.05%, Group 4=0.95%, 
Group 5=1.2%, Group 6=1.0 5% , Group 7=1.4%) . These values are 
not outside the normal range . 
The laboratory conducting this test also reported 
sulfhemoglobin as a percent of hemoglobin for each group 
(Group l=0 . 65%, Group 2=1.45%, Group 3=2.15%, Group 4=2.80%, 
Group 5=1.50%, Group 6=2.75%, Group 7=3 .90%) . An interesting 
observation in this limited sampling was that the sulfhemo-
globin concentration tended to increase as the dose of either 
drug was i ncreased . Normal sulfhemoglobin levels are con-
sidered to be below 1 .0 percent in humans by the laboratory 
that conducted the tests . This test has not been routinely 
conducted in cats so reference values are not known, but 
there is no reason to believe that the 1.0 percent value 
should be exceeded in normal cats. Further trials would need 
to be performed to determine if the sulfur of MHA and MET was 
a contributing factor in the increased sulfhemoglobin 
concentrations found in the treated animals in this study. 
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Liver enzymes 
Alkaline phosphatase (ALP) and alanine aminotransferase 
(ALT) values were not significantly altered by the 
treatments. There was not any apparent effect on the liver 
by either of the two drugs using lack of change in the 
concentration of either of these two enzymes as the criteria. 
The values may be compared in Table 8 and Table 9, 
respectively, for each enzyme. 
Table 8. Alkaline phosphatase means in IU/L, standard error 
of means, F-values, and probabilities of 
significance for treatment groups prior to 
treatment (baseline), during treatment (time 3 
Group 
1 
2 
3 
4 
5 
6 
7 
Standard 
F-Value 
Pr > F 
and 4), and after treatment (time 5) 
Level of 
Treatment 
None-Control 
Low MHA 
Med MHA 
High MHA 
Low MET 
Med MET 
High MET 
Error of 
Means 
Baseline 
Time 
1, 2 
30.8 
18 . 5 
35.8 
27.9 
23.9 
33 . 3 
22.3 
5 . 1 
1. 50 
0.2576 
Time 
3 
28 . 7 
17.8 
38 . 7 
31. 7 
21. 8 
27.8 
21. 5 
5.4 
1. 69 
0.2077 
Time 
4 
24.5 
20.0 
41.3 
34.3 
26.7 
26.7 
26.6 
6.4 
1. 23 
0.3584 
Time 
5 
32.3 
21.2 
49.2 
37.2 
26.5 
31.2 
21. 4 
7.0 
1.91 
0.1610 
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Table 9. Alanine aminotransferase means in IU/L, standard 
error of means, F-values, and probabilities of 
significance for treatment groups prior to 
treatment (baseline) , during treatment (time 3 
and 4), and after treatment (time 5) 
Group 
1 
2 
3 
4 
5 
6 
7 
standard 
F-Value 
Pr > F 
Level of 
Treatment 
None-Control 
Low MHA 
Med MHA 
High MHA 
Low MET 
Med MET 
High MET 
Error of 
Means 
Serum electrolytes 
Baseline 
Time 
1, 2 
84.3 
73.0 
178.3 
145 . 0 
73 . 1 
74 . 3 
93 . 8 
28 . 8 
2.10 
0.1285 
Time 
3 
84.3 
78 . 3 
109.5 
156.3 
73 . 3 
71. 5 
83.2 
25 . 9 
1. 37 
0.3008 
Time 
4 
89.3 
109.5 
159.5 
280.7 
81. 3 
61. 5 
76 . 6 
65 . 4 
1. 34 
0 . 3131 
Time 
5 
123.3 
95 . 0 
168.8 
142.6 
73 . 5 
60.5 
79 . 2 
30 . 7 
1. 63 
0.2224 
Four of the six serum electrolytes measured; sodium, 
chloride, calcium, and magnesium, were found not to be 
significantly changed by the treatments. Tables 10 
through 13 provide the comparison of the concentration of 
these four electrolytes at various collection times of the 
study . 
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The variation in sodium serum concentration was slight 
in this study, both between groups and within groups, as seen 
in Table 10. 
Table 10. Serum sodium concentration means in mEq/L, standard 
error of means, F-values, and probabilities of 
significance for treatment groups prior to 
treatment (baseline), during treatment (time 3 
Group 
1 
2 
3 
4 
5 
6 
7 
Standard 
F-Value 
Pr > F 
and 4) -, and after treatment (time 5) 
Level of 
Treatment 
None-Control 
Low MHA 
Med MHA 
High MHA 
Low MET 
Med MET 
High MET 
Error of 
Means 
Baseline 
Time 
1, 2 
156 . 5 
155 . 3 
156 . 9 
155.0 
157.0 
155 . 8 
155.9 
0.72 
1.11 
0.4122 
Time 
3 
155.0 
155.0 
154.8 
154.5 
154.2 
154.0 
153.5 
0.70 
Time 
4 
154.7 
153.5 
154.8 
153.3 
153.8 
154.3 
153.4 
0.72 
0.66 0.68 
0.6798 0.6692 
Time 
5 
154.7 
153.8 
154.4 
152.8 
154.8 
154.0 
154.8 
0.70 
0.99 
0.4731 
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The mean chloride values in Table 11 demonstrate that 
the serum chloride concentration varied little among groups. 
The chloride concentration did not vary inversely with the 
change in bicarbonate concentration (Table 35). The rion-
hyperchloremic metabolic acidosis that occurred in this study 
is discussed later. 
Table 11. Serum chloride concentration means in mEq/L, 
standard error of means, F-values, and 
probabilities of significance for treatment groups 
prior to treatment (baseline) , during treatment 
(time 3 and 4), and after treatment (time 5) 
Group 
1 
2 
3 
4 
5 
6 
7 
Standard 
F-Value 
Pr > F 
Level of 
Treatment 
None-Control 
Low MHA 
Med MHA 
High MHA 
Low MET 
Med MET 
High MET 
Error of 
Means 
Baseline 
Time 
1, 2 
123.8 
124.1 
124 . 3 
123 . 4 
124.3 
123 . 8 
124.0 
0.78 
0 . 15 
0.9849 
Time 
3 
122.5 
123.7 
123.3 
124.3 
122.5 
123.7 
123.0 
0.56 
1. 42 
0.2852 
Time 
4 
123.7 
123.8 
124.5 
124.5 
122.2 
124.2 
124.0 
0.77 
1.08 
0.4253 
Time 
5 
123.7 
123.5 
122.8 
122.0 
122.2 
121. 8 
123.0 
0.87 
0.70 
0 . 6534 
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Tables 12 and 1 3 demonstrate that serum calcium or 
magnesium concentrations were not affected by a seven day 
treatment with the urinary acidifiers used in this study. 
Table 12 . Serum calcium concentration means in mg/dl, 
standard error of means, F-values, and 
probabilities of significance for treatment groups 
prior to treatment (baseline), during treatment 
(time 3 and 4), and after treatment (time 5) 
Group 
1 
2 
3 
4 
5 
6 
7 
Standard 
F-Value 
Pr > F 
Level of 
Treatment 
None-Control 
Low MHA 
Med MHA 
High MHA 
Low MET 
Med MET 
High MET 
Error of 
Means 
Baseline 
Time 
1, 2 
9 .7 
9.4 
9 . 8 
9.8 
10 . 0 
9 . 6 
9.8 
0.24 
0.52 
0. 7802 
Time 
3 
9 . 5 
9 . 4 
9 . 5 
10.0 
9.6 
9.7 
9.5 
0.26 
0 .67 
0.6769 
Time 
4 
9 . 8 
9 . 2 
9 . 6 
10 . 7 
9.7 
9.7 
9.5 
0 . 57 
0 . 63 
0. 7063 
Time 
5 
9.5 
9 . 1 
9 . 7 
9.2 
9.6 
9.7 
9.3 
0. 30 
0.57 
0.7502 
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Table 13. Serum Magnes i um concentration means in mEq/L, 
standard error of means, F-values, and 
probabilities of significance for treatment groups 
prior to treatment (baseline) , during treatment 
(time 3 and 4), and after treatment (time 5) 
Level of 
Group Treatment 
1 None-Control 
2 Low MHA 
3 Med MHA 
4 High MHA 
5 Low MET 
6 Med MET 
7 High MET 
Standard Error of 
Means 
F-Value 
Pr > F 
Blood ammonia 
Baseline 
Time 
1, 2 
1.9 
1.9 
1. 9 
1. 9 
1. 8 
1.9 
1. 8 
0 . 06 
0 . 55 
0 . 7624 
Time 
3 
2 . 0 
2. 0 
1. 9 
1. 8 
1. 8 
1. 9 
1. 8 
0 . 06 
2 . 5 5 
0 . 0791 
Time 
4 
2 . 1 
2 . 0 
2 . 0 
2.1 
2.0 
2 . 0 
1. 9 
0 . 09 
0. 3 6 
0.8891 
The ammonia concentration in the blood was not 
Time 
5 
1. 8 
1. 9 
1. 9 
1. 9 
1. 9 
1 . 9 
1. 9 
0 . 04 
1. 09 
0.4222 
significantly changed by the treatments . The amino group 
that meth i onine contains and the hydroxy analogue lacks did 
not have a significant effect on blood ammonia as seen in 
Table 14 . Unless liver metabolism is altered or venous 
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shunting is present, the ammonia levels in the blood, as 
measured in this study, would not be expected to be affected 
by the use of either of these two drugs, even at high doses. 
Table 14. Blood Ammonia means in mg/dl, standard error of 
means, F-values, and probabilities of significance 
for treatment groups prior to treatment (baseline) , 
during treatment (time 3 and 4), and after 
treat ment (time 5) 
Group 
1 
2 
3 
4 
5 
6 
7 
Standard 
F-Value 
Pr > F 
Blood pH 
Level of 
Treatment 
None-Control 
Low MHA 
Med MHA 
High MHA 
Low MET 
Med MET 
High MET 
Error of 
Means 
Baseline 
Time 
1, 2 
0.39 
0 . 36 
0 . 34 
0 . 31 
0.38 
0.37 
0.27 
0 . 04 
1. 00 
0 . 4707 
Time 
3 
0.22 
0.28 
0.14 
0.33 
0.35 
0.27 
0.27 
0.06 
1. 00 
0.4671 
Time 
4 
0.59 
0.42 
0.35 
0.32 
0.41 
0.45 
0.26 
0.07 
2.32 
0.1008 
Time 
5 
0.38 
0.41 
0 . 31 
0 . 31 
0.36 
0.39 
0.34 
0.06 
0.37 
0.8839 
Blood pH did not change significantly among treatments, 
although significance was approached (P <0.0675) at Time 4. 
The pH ranged from a low of 7.182 to a high of 7.295 during 
the study. After three days of treatment the high MET group 
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had a mean pH of 7.204 (n = 6). Seven days of treatment were 
required for the high MHA group to reach an average pH of 
7.203 (n = 6). After seven days the high MET group's pH had 
dropped further to a mean pH of 7.182 (n = 5) while the 
control group's blood pH was 7.280 (n = 6). The cats' 
adaption to the metabolic acidosis that developed is evident 
by minimal change in blood pH that may be seen for all groups 
except , possibly, Group 4 and Group 7, which are the high 
dose groups of each drug, in Table 15. 
Table 15 . Blood pH means in pH units, standard error of 
means , F-values, and probabilities of significance 
for treatment groups prior to treatment (baseline), 
during treatment (time 3 and 4), and after 
treatment (time 5) 
Group 
1 
2 
3 
4 
5 
6 
7 
Standard 
F-Value 
Pr > F 
Level of 
Treatment 
None-Control 
Low MHA 
Med MHA 
High MHA 
Low MET 
Med MET 
High MET 
Error of 
Means 
Baseline 
Time 
1, 2 
7.255 
7.248 
7 . 270 
7 . 246 
7 . 245 
7.292 
7.239 
0 . 016 
1. 35 
0.3106 
Time 
3 
7.291 
7.274 
7.259 
7.225 
7 . 242 
7.243 
7.204 
0.024 
1. 56 
0.2422 
Time 
4 
7.280 
7.273 
7.260 
7.203 
7.295 
7.244 
7.182 
0.024 
2.70 
0 . 0675 
Time 
5 
7.292 
7.267 
7.275 
7.294 
7.284 
7.267 
7.259 
0.015 
1. 24 
0.3525 
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Bl ood pco2 
The reduction in blood co2 as an adaptive measure to 
compensate the metabolic acidosis is evident i n the treated 
groups. However, this decrease was not statistically 
significant among groups at any treatment time. The largest 
decrease was in the high MET group . Table 16 provides a 
comparison of pco2 values. 
Table 16. pco2 means in mm/Hg, standard error of means, 
F-values, and probabilities of significance for 
treatment groups prior to treatment (baseline) , 
during treatment (time 3 and 4), and after 
treatment (time 5) 
Group 
1 
2 
3 
4 
5 
6 
7 
Standard 
F-Value 
Pr > F 
Level of 
Treatment 
None-Control 
Low MHA 
Med MHA 
High MHA 
Low MET 
Med MET 
High MET 
Error of 
Means 
Baseline 
Time 
1, 2 
47. 5 
47.9 
46 . 6 
44.8 
47.9 
42.3 
46.0 
2.51 
0.66 
0.6844 
Time 
3 
43.9 
44 . 1 
44 . 1 
41. 7 
44.7 
41.9 
39.3 
2.54 
0.59 
0.7338 
Time 
4 
45.8 
41. 9 
42 . 3 
40.4 
40.7 
41 . 4 
36.2 
2.26 
1. 49 
0.2614 
Time 
5 
44.0 
45.7 
44.4 
43.2 
48.5 
45 . 3 
44.7 
2.28 
0.57 
0.7438 
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Necropsy 
The complete necropsies performed on the six cats in the 
first replication and on the ten cats in the second replica-
tion revealed no gross abnormalities in any of the animals . 
All the animals necropsied were in excellent condition with 
an abu ndance of subcutaneous and internal body fat. 
Histopatholoqy 
The microscopic examination of the tissues did not 
demonstrate any differences between the animals receiving the 
various treatments and the control animals. The s pecial 
staining techniques employed revealed that the vacuoles 
present in the tubule lining cells of the kidney and the 
hepatocytes of the liver contained glycogen in both control 
and treatment groups. 
Par amet ers with Variati ons Among Tr eat ment s 
The test parameters with group mean values that were 
significantly different and that could be related to the 
treatment effects included the following: 
Daily feed intake 
Urine 
Blood 
General 
Phosphorus, Magnesium, Urea nitrogen, Ammonia 
pH, Titratable acidity. 
Phosphorus, Potassium, Bicarbonate, Heinz body 
formation. 
Two deaths, Toxicosis. 
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Tables containing the mean of each parameter by group at 
each sample time are listed with a brief discussion of the 
results preceding each one. In addition to the standard 
error of means, F-value and probability of significance at 
each time period, tables of statistical comparisons between 
control and treatments and between the two drugs are made to 
further clarify the effects. Selected measurements at 
specific treatment times comparing the three doses of each 
drug to each other and to the control group at a given time 
are presented in graphical form . 
Daily food intake 
Daily food intake was affected by the treatments. Since 
the twenty-four hour food intake was calculated every day for 
the entire study, this measurement was divided into three 
time periods: the first being the fourteen day pre-dosing 
period, the second being the seven day dosing period, and the 
third being the seven day post-dosing period. The pre-dosing 
and post-dosing periods did not show significant differences 
in average daily food intake among treatment groups. There 
were significant differences during the treatment period. No 
satisfactory explanation can be given to explain the decrease 
in food intake by the non-treated control group during the 
dosing period. Table 17 provides the average daily food 
intake for each group during each period. 
68 
Table 17. Daily food intake means in grams, standard error of 
means, F-values, and probabilities of significance 
for treatment groups during pre-dosing, dosing and 
post-dosing periods. 
Level of Periods 
Group Treatment 
Pre-Dosing Dosing Post-Dosing 
1 None-Control 75.6 65.2 68.9 
2 Low MHA 80.6 79.2 83.9 
3 Med MHA 85.2 78 . 2 85.9 
4 High MHA 82.7 54 .5 82.8 
5 Low MET 79 . l 74.7 89.4 
6 Med MET 79 . 6 54.2 74.5 
7 High MET 78.8 39.4 66.1 
Standard Error of 6 . 7 2 . 1 5.8 
Means 
F-Value 0.20 5.15 1.98 
Pr > F 0.9686 0.0078 0.1483 
During the seven day dosing period, the average daily 
food consumption of the MHA and MET groups were significantly 
different (P <0.0193) from each other but not from the 
control group (P <0.8045) . The decline in food intake was 
linear with respect to increase in dose with both drugs (MHA, 
P <0.0209 and MET, P <0.0026). The statistical comparisons 
of mean daily food intake are given in Table 18. 
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Table 18. Comparisons of daily food intake during the seven 
day dosing period between control group and all 
treatment groups, between MHA and MET groups, and 
for linear and quadratic models for MHA and MET 
Comparisons During Treatment Period 
F-Value Pr > F 
Control vs. Treatments 0.66 0.8045 
MHA vs. MET 7.29 0.0193 
Linear MHA 7.05 0.0209 
Quadratic MHA 1.97 0 . 1859 
Linear MET 14.44 0 .0026 
Quadratic MET 0.12 0.7329 
The food intake of the low MHA and MET groups were 
similar . The decline in food intake in those cats receiving 
the medium MET treatment and the high MHA dose were similar . 
The high MET dose resulted in somewhat greater decline in 
food intake. The graph in Figure 1 demonstrates that the 
linear decline in food intake with respect to dose was faster 
and greater in the MET treated groups than in the MHA groups. 
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Figure 1. Average daily food intake for control, 3 MHA 
and 3 MET treatment groups during the seven day 
dosing period 
The reduction in food intake is a prominent toxicological 
alteration that the high dose of MHA and the medium and high 
dose of MET affected in this study . 
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uri nary phosphor u s 
Table 19 gives the tabulation of urinary phosphorus 
values and demonstrates that there were significant 
differences among groups at both Time 3 (P <0.0001) and 
Time 4 (P <0 . 0161). 
Table 19. Urinary phosphorus means in mg/dl, standard error 
of means, F-values, and probabilities of 
significance for treatment groups prior to 
treatment (baseline) , during treatment (time 3 and 
4), and after treatment (time 5) 
Group 
1 
2 
3 
4 
5 
6 
7 
Standard 
F-Value 
Pr > F 
Level of 
Treatment 
None-Control 
Low MHA 
Med MHA 
High MHA 
Low MET 
Med MET 
High MET 
Error of 
Means 
Baseline 
Time 
1, 2 
257.0 
237.0 
282.0 
239.0 
282.4 
274 . 8 
247.1 
20.6 
0 .93 
0.5093 
Time 
3 
233 . 5 
231. 7 
217.5 
127.5 
280.5 
314.3 
284.8 
14.9 
16.82 
0.0001 
Time 
4 
242.0 
212.0 
214.2 
186.3 
279.0 
323.0 
309.2 
24.7 
4.24 
0.0161 
Time 
5 
238 . 3 
251. 3 
268.8 
256.2 
276.6 
263.9 
284 . 8 
14.3 
1. 07 
0.4304 
Table 20 summarizes the comparisons of groups that were 
made at Time 3 and Time 4 and provides statistical data that 
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suggest that the treatment groups were not significantly 
different from the control group in the amount of phosphorus 
excreted in the urine . The MHA groups and the MET groups 
were found to be different from each other at a high degree 
of significance at both sample Time 3 (P <0.0001) and sample 
Time 4 (P <0.0006). 
Table 20. Comparisons of urinary phosphorus concentrations 
at Time 3 and 4 between control group and all 
treatment groups, between MHA and MET groups, and 
for linear and quadratic models for MHA and MET 
Comparisons Time 3 Time 4 
F-Value Pr > F F-Value Pr > F 
Control vs. Treatments 0 .33 0 . 5775 0 .14 0.7176 
MHA vs . MET 68.83 0.0001 21. 26 0.0006 
Linear MHA 24.40 0.0003 0.54 0.4765 
Quadratic MHA 4 .3 1 0.0600 0 . 25 0 . 6289 
Linear MET 0 . 04 0.8406 0.21 0.6571 
Quadratic MET 3.01 0.1085 1. 36 0.2660 
MHA demonstrated a significant linear tendency to cause 
a decline in urinary phosphorus as the dose increased at 
Time 3 (P <0.0003) . This tendency was not present after 
treatments had been given for seven days . The urinary 
phosphorus levels tended to be lower in the MHA groups and 
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higher in the MET groups. The reasons for thi s require 
further study. Figure 2 and Figure 3 graphic ally demonstrate 
urinary phosphorus levels at Ti me 3 and Time 4, respectively, 
for control and treatment groups . 
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Figure 2. Urinary phosphorus concentrations for control, 3 
MHA and 3 MET treatment groups after three days of 
treatments 
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The higher phosphorus concentration in the urine of the 
cats in the MET groups is possibly a reflection of the higher 
titratable acidity values in these groups. Phosphorus in the 
form of phosphate is part of a buff er system which aids in 
the elimination of the hydrogen ion that resulted from the 
metabolic acidosis of the treatments. The excess hydrogen 
ion production in the highest dose groups may result in the 
depletion of the phosphate buffer, accounting for the 
decrease of phosphorus as the dose increased. 
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Figure 3. Urinary phosphorus concentrations for control, 3 
MHA and 3 MET treatment groups after seven days of 
treatments 
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Urinary magnesium 
Treatment with either drug at all dosage levels resulted 
in an increase in urinary magnesium values when compared to 
controls. Table 21 gives the comparison of the magnesium 
levels between groups at each sample time. The increase was 
not strictly dose related. 
Table 21. Urinary magnesium means in mEq/L, standard error of 
means, F-values, and probabilities of significance 
for treatment groups prior to treatment (baseline) , 
during treatment (time 3 and 4), and after 
treatment (time 5) 
Group 
1 
2 
3 
4 
5 
6 
7 
Standard 
F-Value 
Pr > F 
Level of 
Treatment 
None-Control 
Low MHA 
Med MHA 
High MHA 
Low MET 
Med MET 
High MET 
Error of 
Means 
Baseline 
Time 
1, 2 
10.9 
10.2 
11. 7 
10.0 
10.3 
17.1 
12.8 
2.5 
1. 00 
0.4672 
Time 
3 
7.9 
14.8 
20.0 
16.4 
22.9 
15.6 
11. 4 
2.0 
6.09 
0.0040 
Time 
4 
10.9 
15 . 9 
19.4 
20.8 
19.4 
18.3 
14.1 
2.8 
1. 56 
0.2404 
Time 
5 
5.5 
5.8 
7.7 
8.8 
11. 6 
7.4 
9.2 
2.3 
0.85 
0.5571 
There did seem to be a tendency for an increasing MHA 
dose to cause an increase in magnesium excretion and an 
increasing MET dose a decreasing trend. A linear model could 
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be applied to MET at three days but not at seven days . 
During the dosing period the difference in urinary magnesium 
levels between the control group and the treatment groups was 
significant at both Time 3 (P <0.0015) and Time 4 
(P <0.0449). The two drugs were not found to be 
significantly different in their effect on magnesium urinary 
excretion. The statistical comparisons are found in 
Table 22 . 
Table 22 . Comparisons of urinary magnesium concentrations 
at Time 3 and 4 between control group and all 
treatment groups, between MHA and MET groups, and 
for linear and quadratic models for MHA and MET 
Comparisons Time 3 Time 4 
F-Value Pr > F F-Value Pr > F 
Control vs. 
Treatments 16.62 0.0015 5.01 0.0449 
MHA vs . MET 0.06 0.8062 0.74 0.4051 
Linear MHA 0.31 0.5883 1. 51 0 . 2422 
Quadratic MHA 3.12 0.1028 0.09 0.773 3 
Linear MET 16.03 0.0018 2.61 0 . 132 2 
Quadratic MET 0.40 0.5391 0.45 0.5155 
urinary urea nitrogen 
The urinary urea nitrogen data are provided in Table 23 . 
Treatments were different only at Time 3. It may be noted 
that high doses of each drug had a tendency to cause a 
decrease in urea. This may represent a shift in nitrogen 
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excretion away from urea and to ammonium which may be 
associated with the metabolic acidosis that occurred in the 
high MHA and MET groups. Alternatively, this may represent a 
decline in urea formation because of decreased food intake, 
especially at the high doses of the drugs. 
Table 23. Urinary urea nitrogen means in mg/dl, standard 
error of means, F-values, and probabilities of 
significance for treatment groups prior to 
treatment (baseline) , during treatment (time 3 and 
4), and after treatment (time 5) 
Level of 
Group Treatment 
1 None-
Control 
2 Low MHA 
3 Med MHA 
4 High MHA 
5 Low MET 
6 Med MET 
7 High MET 
Standard Error of 
Means 
F-Value 
Pr > F 
Baseline 
Time 
1, 2 
4709.0 
4884.1 
5136.8 
4742.8 
4974.4 
5149.6 
4932.2 
194.8 
0.79 
0.5978 
Time 
3 
4511. 7 
5175.0 
4941. 7 
3561.7 
4693.3 
4140.8 
3759.2 
195.0 
9.52 
0.0006 
Time 
4 
4725.8 
4901. 3 
4920.8 
4492.5 
4861. 7 
4650.2 
4302.0 
278.2 
0.62 
0.7095 
Time 
5 
4779.5 
5370.2 
5476.0 
4880.0 
5173.7 
5513.5 
5496.4 
237.2 
1.59 
0 . 2329 
It is demonstrated in Table 24 that after three days of 
treatment urinary urea nitrogen concentration demonstrated a 
linear tendency to decline in response to increased dose of 
each of the drugs. However, this did not occur after seven 
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days of treatment, and at none of the sample times, including 
Time 3, was the control group different from the treatment 
groups . 
Table 24. Comparisons of urinary urea nitrogen 
concentrations at Time 3 and 4 between control 
group and all treatment groups, between MHA and 
MET groups, and for linear and quadratic models 
for MHA and MET 
Comparisons Time 3 Time 4 
F-Value Pr > F F-Value Pr > F 
Control vs . 0 . 40 0.5394 0 . 01 0 . 9381 
Treatments 
MHA vs. MET 5. 16 0 . 0423 0 . 36 0 . 5618 
Linear MHA 34 . 22 0 . 000 1 1. 08 0 . 3193 
Quadratic MHA 5 . 76 0 . 0335 0 . 43 0 . 5235 
Linear MET 11 . 77 0 . 0054 1. 26 0 . 2840 
Quadratic MET 0 . 13 0.7268 0.01 0.9402 
The graphs in Figure 4 and Fi gure 5 depict the urinary urea 
nitrogen at Time 3 and Time 4, respectively, for the seven 
groups. 
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Fi gure 4 . Urinary urea nitrogen concentrations for control, 3 
MHA and 3 MET treatment groups after three days of 
treatments . 
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Figure 5. Urinary urea n i trogen concentrations for control, 3 
MHA and 3 MET treatment groups after seven day s of 
treatment. 
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Urinary ammonia 
The urinary ammonia concentrations for the study are 
provided in Table 25. The treatments caused an increase in 
the concentration of ammonia in the urine when compared to 
the controls. The ammonia concentrations were higher in the 
MHA treated cats and lower in the MET groups at all three 
doses . 
Table 25. Urinary ammonia means in mg/dl, standard error of 
means, F-values, and probabilities of significance 
for treatment groups prior to treatment (baseline) , 
during treatment (time 3 and 4), and after 
treatment (time 5) 
Level of 
Group Treatment 
1 None-
Control 
2 Low MHA 
3 Med MHA 
4 High MHA 
5 Low MET 
6 Med MET 
7 High MET 
Standard Error of 
Means 
F-Value 
Pr > F 
Baseline 
Time 
1, 2 
43 .1 
44.0 
41.1 
43 . 9 
43.2 
41. 8 
42 .3 
1. 3 
0 .7 0 
0.6521 
Time 
3 
41. 4 
48.4 
49.3 
57.9 
44.4 
47.2 
50.6 
3.0 
2.99 
0.0504 
Time 
4 
38 .8 
51. 3 
51.1 
59.3 
42 . 7 
45.6 
51. 9 
3.2 
4.45 
0 .0135 
Time 
5 
42.8 
50.2 
43.6 
45.6 
39.2 
46.4 
41.1 
2 . 9 
1. 57 
0 . 2383 
During the dosing period the urinary ammonia levels 
increased as the dosage level of the two drugs was increased . 
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This increase was significantly different than the control 
level at Time 3 (P <0.0260) and at Time 4 (P <0.0061). After 
seven days of treatment the excretion of ammonia was 
significantly different (P <0.0232) between the MHA groups 
and the MET groups . Table 26 gives the comparison. 
Table 26. Comparisons of urinary ammonia concentrations at 
Time 3 and 4 between control group and all 
treatment groups, between MHA and MET groups, and 
for linear and quadratic models for MHA and MET 
Comparisons Time 3 Time 4 
F-Value Pr > F F-Value Pr > F 
Control vs. 
Treatments 6 . 44 0.0260 11. 01 0.0061 
MHA vs . MET 3.31 0 . 0937 6 . 76 0 . 0232 
Linear MHA 5.02 0 . 0448 3.09 0.1041 
Quadratic MHA 1. 07 0.3213 1.13 0 .3081 
Linear MET 2.09 0 . 1741 3 . 93 0 . 0709 
Quadratic MET 0 . 00 0 .9480 0 .2 3 0.6410 
The graphs in Figure 6 and Figure 7 depict the urinary 
ammonia values at Time 3 and Time 4, respectively, for the 
seven groups . 
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Figure 6 . Urinary ammonia concentrations for control, 3 MHA 
and J MET treatment groups after three days o f 
treatments 
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Figure 7. Urinary ammonia concentrations for control, 3 MHA 
and 3 MET treatment groups after seven days of 
treatment 
The rise i n the uri nary ammonia concentration associated 
with the use of the urinary acidifiers MHA and MET may 
represent a normal compensatory response by the renal tubular 
epithelial cells in secr eti ng ammonia into the tubular lumen 
i n order to reduce acidity by the subsequent formation of 
ammonium ion which effectively traps the hydrogen ion for 
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excretion in the urine. 110 The alternative explanation is 
that the major reason for excretion of hydrogen ions is to 
trap ammonia, and that the ammonium ion in the urine does not 
represent excretion of acid. 105 An explanation to account 
for increased urinary ammonia in the MHA groups compared to 
the MET groups cannot be satisfactorily made without further 
studies. It is interesting to note that titratable acidity 
values were higher for MET groups and lower for the MHA 
groups (reversed to the urinary ammonia) indicating that in 
this study the hydrogen i ons may have been disposed in 
slightly different ways for MHA and MET . The phosphate 
buffering system appeared to be more involved in eliminating 
the hydrogen ion in the MET treated cats and the 
ammonia/ammonium buffering system in hydrogen ion elimination 
in the MHA treated cats . This will require further study. 
Uri nar y pH 
The urinary pH was decreased following all doses of MHA 
and MET to below the target pH of 6.6 necessary to prevent 
struvite formation in the urine . Table 27 demonstrates that 
steady state appears to have been reached by three days of 
treatment as the pH at each of the 3 doses of each drug are 
similar when compared to the pH of the urine after seven 
days . It should also be emphasized that the lowest dose for 
86 
each drug would be adequate to provide the proper urinary pH 
to preclude struvite precipitation and formation in the urine 
of cats. 
Table 27. Urinary pH means in pH units, standard error of 
means, F-values, and probabilities of significance 
for treatment groups prior to treatment (baseline), 
during treatment (time 3 and 4), and after 
treatment (time 5) 
Level of 
Group Treatment 
1 None-
Control 
2 Low MHA 
3 Med MHA 
4 High MHA 
5 Low MET 
6 Med MET 
7 High MET 
Standard Error of 
Means 
F-Value 
Pr > F 
Baseline 
Time 
1, 2 
6 .72 
6.78 
6 . 56 
6 . 59 
6.55 
6.71 
6.58 
0.11 
0.66 
0.6801 
Time 
3 
6.84 
6.38 
6 . 09 
5 . 86 
5.98 
5.87 
5.82 
0 .07 
26.14 
0.0001 
Time 
4 
6.68 
6.39 
5.99 
5.93 
6.17 
5.92 
5.93 
0.09 
11.35 
0 .0002 
Time 
5 
6.93 
6.89 
6.79 
6 . 65 
6.67 
6.80 
6 .79 
0.14 
0.46 
0.8222 
Table 28 provides further comparisons of the groups. 
After three days or seven days of treatment the pH of the 
urine of the cats in the control group was significantly 
different (P <0.0001) than the treatment groups. After three 
days of dosing the MHA groups and MET groups were 
statistically different (P <0.0028) from each other as 
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indicated by the variation in the reduction of urinary pH. 
Also, MHA caused a significant (P <0.0003) linear decline in 
urinary pH values at Time 3 as the dose was increased. MET 
treatments did not demonstrate a dose related decline in pH. 
The decline in urinary pH was similar at all three doses for 
the MET treated groups at Time 3. After the treatments had 
been applied for seven days, the MHA groups were no longer 
statistically different from the MET groups in lowering the 
urinary pH . However, the linear model still described the 
decline of pH with increase in dose (P <0.0027) for the MHA 
groups . 
Table 28 . Comparisons of urinary pH at Time 3 and 4 between 
control group and all treatment groups, between 
MHA and MET groups, and for linear and quadratic 
models for MHA and MET 
Compari sons Time 3 Time 4 
F-Value Pr > F F-Value Pr > F 
Control v s . 
Treatments 115.20 0.0001 44 .93 0 . 0001 
MHA vs. MET 13 . 96 0.0028 1. 81 0.2035 
Linear MHA 25. 16 0.0003 14.14 0.0027 
Quadratic MHA 0 . 08 0.7841 2 .6 2 0.1315 
Linear MET 2.36 0.1502 2.92 0.1131 
Quadratic MET 0.11 0.7493 1. 61 0.2289 
The decline of urinary pH is further demonstrated by 
the graphs in Figure 8 and Figure 9. 
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Figure 8. Urinary pH values for control, 3 MHA and 3 MET 
treatment groups after three days of treatment 
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Figure 9. Urinary pH values f or control, 3 MHA and 3 MET 
treatment groups after seven days of treatment 
Urinary t i tratable a cidity 
Twenty-four hour titratable acidity to pH 7.4 was 
significantly different among groups during treatment at 
Time 3 (P <0.0001) and Ti me 4 (P <0.0006) . The titratable 
acidity values to 7.4 were generally lower for the MHA 
treatment groups and higher for the MET treatment groups. 
Table 29 provides the data for this measurement. 
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Table 29. Urinary titratable acidity to pH 7.4 means, 
standard error of means, F-values, and 
probabilities of significance for treatment groups 
prior to treatment (baseline), during treatment 
(time 3 and 4), and after treatment (time 5) 
Level of 
Group Treatment 
1 None-
Control 
2 Low MHA 
3 Med MHA 
4 High MHA 
5 Low MET 
6 Med MET 
7 High MET 
Standard Error of 
Means 
F-Value 
Pr > F 
Baseline 
Time 
1, 2 
1. 63 
1. 57 
2.48 
2.36 
1. 64 
2.03 
1. 98 
1.41 
0 .80 
0.5871 
Time 
3 
1.13 
2.13 
2.87 
2.35 
3.87 
5.97 
4.38 
0.33 
24.77 
0.0001 
Time 
4 
1.47 
2 . 25 
3.42 
3.01 
2.97 
5.02 
4.66 
0.40 
9.52 
0.0006 
Time 
5 
1. 00 
1.02 
1. 48 
2.12 
1. 72 
1.67 
1. 74 
0.43 
0.73 
0.6352 
During the dosing period significant differences were 
demonstrated between the control group and the treatment 
groups (Time 3, P <0.0001 and Time 4, P <0.0004) for 
titratable acidity to pH 7.4. The comparison of titratable 
acidity the cats in the MHA groups and those in the MET 
groups revealed a significant difference at both Time 3 
(P <0.0001) and Time 4 (P <0.0023). 
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The titratable acidity of urine is largely dependent on 
the amount of mono and dibasic phosphate present. The 
equivalents of base required to titrate a urine specimen to 
physiologic pH of 7.4 is equal to the excretion of hydrogen 
ions except for those eliminated as ammonium ion. Table 30 
summarizes these statistical comparisons. 
Table 30. Comparisons of urinary titratable acidity to pH 7.4 
at Time 3 and 4 between control group and all 
treatment groups, between MHA and MET groups, and 
for linear and quadratic models for MHA and MET 
Comparisons Time 3 Time 4 
F-Value Pr > F F-Value Pr > F 
Control vs. 
Treatments 49 . 06 0.0001 23.05 0.0004 
MHA vs. MET 74.25 0.0001 14.90 0.0023 
Linear MHA 0.22 0.6461 1. 86 0.1982 
Quadratic MHA 2 .46 0.1427 2.58 0.1340 
Linear MET 1.26 0.2834 6.93 0 . 0219 
Quadratic MET 21. 37 0.0006 6.23 0.0281 
The titratable acidity to pH 7.4 is graphically depicted 
in Figure 10 and Figure 11 at Time 3 and Time 4, 
respectively . The graphs demonstrate that the quadratic 
model (P <0.0006 at Time 3 and P <0 . 0281 at Time 4) best 
represent the response to increasing MET dosage. 
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Figure 10 . Urinary titratable acidity to pH 7.4 for 
control, 3 MHA and 3 MET treatment groups after 
three days of treatments 
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Figure 11 . Urinary titratable acidity to pH 7 . 4 for 
control, 3 MHA and 3 MET treatment groups after 
seven days of treatments 
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Twenty-four hour titratable acidity to pH 8.4 was 
significantly different among groups during treatment only at 
Time 3 (P <0.0091) and not at Time 4 (P <0.0850). Again the 
titratable acidity values to 8.4 were generally lower for the 
MHA treatment groups and higher for the MET treatment groups. 
Table 31 provides the data for titratable acidity to pH 8.4. 
Table 31. Urinary titratable acidity to pH 8.4 means, 
standard error of means, F-values, and 
probabilities of significance for treatment groups 
prior to treatment (baseline) , during treatment 
(time 3 and 4), and after treatment (time 5) 
Baseline 
Level of Time 
Group Treatment 1, 2 
1 None-Control 3 . 42 
2 Low MHA 3.46 
3 Med MHA 3 . 7 2 
4 High MHA 3 . 95 
5 Low MET 3 . 21 
6 Med MET 4 . 40 
7 High MET 4 . 15 
Standard Error of o. 4 7 
F-Value 
Pr > F 
Means 
0 . 84 
0.5627 
Time 
3 
2.72 
4.03 
4.98 
4.57 
6.17 
4.65 
5.83 
0.52 
4.94 
0.0091 
Time 
4 
3.23 
4.13 
5.88 
3.77 
5.03 
6.75 
4.18 
0.80 
2.48 
0.0850 
Time 
5 
3.02 
2.60 
3.35 
3.40 
3 . 28 
4.30 
3.46 
0.58 
0.79 
0.5954 
For titratable acidity to pH 8.4 significance between 
the control group and the treatment groups occurred at Time 3 
(P <0.0013) and was approached at Time 4 (P <0.0584). The 
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comparison of titratable acidity to pH 8.4 between the MHA 
groups and the MET groups demonstrated significance only at 
Time 3 (P <0.0322). Table 32 summarizes this information. 
Table 32. Comparisons of urinary titratable acidity to 
pH 8.4, at Time 3 and 4 between control group and 
all treatment groups, between MHA and MET groups, 
and for linear and quadratic models for MHA and MET 
Time 3 Time 4 
Comparisons F-Value Pr > F F-Value Pr > F 
Control vs. 
Treatments 17. 31 0 . 0013 4.38 0.0584 
MHA vs. MET 5 . 87 0 . 0322 1. 77 0.2078 
Linear MHA 0 . 53 0 . 4796 0 . 11 0.7502 
Quadratic MHA 1.17 0 . 3015 3.93 0.0707 
Linear MET 0 . 21 0 . 6565 0.09 0.7681 
Quadratic MET 4.55 0 . 0543 3.60 0.0821 
The graph in Figure 12 demonstrates the titratable 
acidity to pH 8.4 at Time 4 after seven days of treatments. 
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Figure 12. Urinary titratable acidity to pH 8.4 for 
control, 3 MHA and 3 MET treatment groups after 
seven days of treatments 
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Serum phosphorus 
Table 33 provides the comparison of the phosphate 
concentrations of the serum. Only at Time 4 is there a 
significant difference among groups (P <0.0245). The most 
apparent difference was the decrease in phosphorus 
concentration at Time 4 for the high MET group. 
Table 33. Serum phosphorus concentration means in mg/dl, 
standard error of means, F-values, and 
probabilities of significance for treatment groups 
prior to treatment (baseline) , during treatment 
(time 3 and 4), and after treatment (time 5) 
Baseline 
Level of Time 
Group Treatment 1, 2 
1 None-Control 6.6 
2 Low MHA 6. 3 
3 Med MHA 6.5 
4 High MHA 6.5 
5 Low MET 6 . 6 
6 Med MET 5.5 
7 High MET 6.2 
Standard Error of O. 3 4 
F-Value 
Pr > F 
Means 
serum potass i um 
1. 31 
0.3238 
Time 
3 
6.0 
6.2 
6.6 
6 . 3 
6.1 
5.5 
5.6 
0.24 
2.53 
0.0811 
Time 
4 
5.8 
5.9 
6.2 
5.7 
6.6 
5.5 
4. 7 
0 . 29 
3.75 
0.0245 
Time 
5 
6.0 
6.1 
6.4 
6.2 
6 . 4 
5.8 
6.1 
0.38 
0 . 32 
0 . 9116 
Serum potassium concentrations were significantly 
different among groups only after the treatments had been 
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given for seven days at Time 4 (P <0.0436). The decrease is 
most evident in the high MHA group and the high MET group. 
This finding is somewhat paradoxical as metabolic acidosis is 
usually associated with hyperkalemia. Urinary potassium was 
not measured so it is not known whether increased excretion 
of potassium also occurred in these groups. Table 34 
provides the serum potassium data . 
Table 34. Serum potassium concentration means in mEq/L, 
standard error of means, F-values, and 
probabilities of significance for treatment groups 
prior to treatment (baseline), during treatment 
(time 3 and 4), and after treatment (time 5) 
Group 
1 
2 
3 
4 
5 
6 
7 
Standard 
F-Value 
Pr > F 
Level of 
Treatment 
None-Control 
Low MHA 
Med MHA 
High MHA 
Low MET 
Med MET 
High MET 
Error of 
Means 
Baseline 
Time 
1, 2 
5.1 
5 . 0 
5 . 0 
5.1 
5 . 3 
5 . 0 
5.0 
0.15 
0 . 69 
0 . 6595 
Time 
3 
4.8 
4.9 
4.9 
4.8 
4.9 
5.0 
4.3 
0.19 
1. 74 
0.1961 
Time 
4 
4.9 
4.9 
5.0 
4.4 
5.0 
4.8 
4.0 
0.20 
3 .13 
0 . 0436 
Time 
5 
5.1 
5.0 
5.2 
5 . 6 
5 . 0 
5.5 
5.5 
0.15 
2.55 
0.0789 
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Blood bicarbonate 
The blood bicarbonate concentrations were lowered by the 
treatments. Table 35 is a tabulation of the bicarbonate 
levels for each group at each collection period. The 
difference was highly significant at Time 3 (P <0.0152) and 
at Time 4 (P <0.0001). 
Table 35. Blood bicarbonate concentrations means in mEq/L, 
standard error of means, F-values, and 
probabilities of significance for treatment groups 
prior to treatment (baseline), during treatment 
(time 3 and 4), and after treatment (time 5) 
Baseline 
Level of Time 
Group Treatment 1, 2 
1 None-Control 20 . 4 
2 Low MHA 20.2 
3 Med MHA 20 . 6 
4 High MHA 18.6 
5 Low MET 20 . 1 
6 Med MET 19 . 8 
7 High MET 19. 2 
Standard Error of o. 68 
F-Value 
Pr > F 
Means 
1. 05 
0.4434 
Time 
3 
20.6 
19.8 
19 . 1 
16 . 6 
18.7 
17 .6 
15.0 
0.93 
4.30 
0.0152 
Time 
4 
21.0 
18.8 
18.4 
15.3 
19.3 
17 .4 
13.1 
0.70 
12.69 
0.0001 
Time 
5 
20.6 
21. 2 
20.2 
20.4 
20 .4 
20.1 
19.3 
0.86 
0.22 
0.9629 
The decline in bicarbonate blood levels was greater as 
the dose of each of the drugs increased. This decline fit a 
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linear model for each drug at Time 3 and Time 4 
(MHA P <0.0336 and P <0.0039, MET P <0.0152 and P <0.0002). 
The two drugs were not found to be statistically different 
from each other in their reduction of blood bicarbonate. 
Table 36 gives the comparison during the treatment period. 
Table 36 . Comparisons of blood bicarbonate concentrations 
at Time 3 and 4 between control group and all 
treatment groups, between MHA and MET groups, and 
for line ar and quadratic models for MHA and MET 
Comparisons Time 3 Time 4 
F-Value Pr > F F-Value Pr > F 
Control vs. 7 . 69 0.0169 25.17 0.0003 
Treatments 
MHA vs . MET 3 . 28 0.0954 1.30 0.2759 
Linear MHA 5.76 0.0336 12.67 0.0039 
Quadratic MHA 0 . 69 0.4237 2.29 0.1564 
Linear MET 8 . 01 0.0152 26.47 0.0002 
Quadratic MET 0.41 0.5357 0.84 0.3782 
Figure 13 and Figure 14 graphically display the 
bicarbonate levels in the blood at collection Time 3 and 
Time 4, respectively. It may be noted that a drop in 
bicarbonate concentration was, in general, greater and faster 
for the MET groups when compared to the MHA groups. 
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Figure 13 . Blood bicarbonate concentrations for control, 3 
MHA and 3 MET treatment groups after three days 
of treatment 
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Figure 14 . Blood bicarbonate concentrations for control, 3 
MHA and 3 MET treatment groups after seven days of 
treatment 
The metabolic acidosis that developed was especially 
severe at the high doses of each drug. As discussed earlier 
the compensatory mechanisms were being overwhelmed at the 
high doses . The anion gap was calculated and was determined 
to be normal for all groups. 
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Heinz body format i on 
Not until the animals had been on the treatments for 
seven days did Heinz bodies appear in the red blood cells of 
the cats in increased numbers . The two drugs caused 
oxidation of hemoglobin, and the resulting increases in Heinz 
body formation were evident at the medium MHA and medium MET 
doses and the high MHA and high MET doses . The average 
number of Heinz bodies per 1000 red blood cells for each 
group at each sample time may be seen in Table 37. The 
decline of Heinz bodies back to the pre-dosing values for the 
cats in this test was not complete by seven days (Time 5) 
after the last treatments . As noted earlier no clinical 
anemia resulted in the cats in this study because of the 
treatments . The Heinz bodies or the RBCs containing them 
were apparently being removed from the circulation without 
any resulting anemia . 
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Table 37. Heinz bodies per 1000 RBC means, standard error of 
means, F-values, and probabilities of significance 
for treatment groups prior to treatment (baseline) , 
during treatment (time 3 and 4), and after 
treatment (time 5) 
Level of 
Group Treatment 
1 None-Control 
2 Low MHA 
3 Med MHA 
4 High MHA 
5 Low MET 
6 Med MET 
7 High MET 
Standard Error of 
Means 
F-Value 
Pr > F 
General observations 
Baseline 
Time 
1, 2 
2.17 
0 . 10 
0 . 50 
0.50 
0 . 50 
0 . 33 
0.25 
0 . 47 
2.21 
0.1145 
Time 
3 
2.17 
0 . 50 
1. 00 
3.67 
0.00 
0 .83 
3 . 33 
1. 37 
1. 07 
0.4333 
Time 
4 
2 . 83 
0 . 83 
83 .00 
474.17 
1.33 
23.33 
606.00 
67.55 
13.52 
0.0001 
Time 
5 
0 . 33 
0 . 33 
16 . 67 
54.40 
0.17 
9.00 
281.00 
55 . 64 
3.10 
0.0450 
Two cats in the first replication died. They exhibited 
extreme listlessness, rapid shal l ow respiration, vomiting, 
dehydration, ataxia, and complete inappetence before they 
died. One , a female, was in the high dose MHA group, and the 
other, a male, was in the high dose MET group. The apparent 
cause of the deaths was the effects of the acute metabolic 
acidosis. 
Several other cats in each of the high dose groups 
displayed toxicological signs of extreme inactivity, rapid 
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shallow breathing, dilated pupils, occasional ataxia and 
reduced or no appetite. Recovery was rapid as soon as the 
treatments were stopped. 
A few cats in the medium MET groups exhibited an 
observed reduction in their activity, but the most apparent 
clinical sign was reduced food intake. The cats in the 
medium MHA group did not exhibit obvious clinical symptoms 
resulting from the treatments. 
The urine of all the treated cats changed from a cloudy 
appearance to clear by the third or fourth day of treatment 
and returned to the original state after the treatments were 
stopped . The odor of the urine in the room in which the cats 
were housed developed a less pungent, offensive odor during 
treatment. 
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CONCLUSIONS 
It was demonstrated in this study that methionine and 
methionine hydroxy analogue effectively lowered the urinary 
pH. The steady state urinary pH was reached in all treatment 
groups by the third day after the treatments were initiated. 
Although monitoring the urinary pH of individual cats is 
desirable in a clinical setting, it was found in this study 
that a single daily dose of 2.5 mEq/kg, which was the low 
dose, of either drug would maintain a urinary pH at 6.6 or 
below. This is the target pH necessary to prevent struvite 
crystal formation in the urine of cats. The potential side 
effects of continuous use of either of the two drugs would 
presumably be lessened, since the low dose of each drug was 
sufficient to accomplish the needed reduction in urinary pH. 
The comparison of the side effects of the two drugs 
revealed that many of the parameters examined in this study 
were unaltered by either drug during a seven day treatment 
period. Before it can be determined if these measurements 
will be influenced by chronic use of these drugs, they will 
need to be monitored in a long-term study. 
The toxicosis caused by the two drugs is prominent at 
the high dose of each. The animals in the medium MET group 
also exhibited side effects. The cats in the medium MHA 
group did not seem to be affected as greatly as their 
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counterparts in the MET group. The side effects noted were 
consistent with clinical manifestations of metabolic 
acidosis . The inactivity that was observed and the reduction 
in daily food intake were the most dramatic clinical changes. 
The elimination of the excess hydrogen ion in the urine 
appeared to be by slightly different urinary buffering 
mechanisms for the two drugs . Whether this would remain a 
consistent difference with prolonged treatment with the two 
drugs will require further study. 
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